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1 
BROADLY PROTECTIVE SHIGELLA 
VACCINE BASED ON TYPE III SECRETION 
APPARATUS PROTEINS 
2 
licensed vaccine for Shigella spp. currently exists. Efforts to 
develop a vaccine against this pathogen have included the 
use of killed bacteria, live attenuated and recombinant 
carrier organisms, polysaccharide conjugates and LPS/pro-
CROSS REFERENCE TO RELATED 
APPLICATION 
This application claims the benefit of U.S. Provisional 
Patent Application Ser. No. 61/568,918 filed on Dec. 9, 
2011, and incorporates said provisional application by ref-
erence into this document as if fully set out at this point. 
5 tein mixtures. When tested in humans, these vaccines were 
either too reactogenic or poorly immunogenic. A major 
disadvantage of these candidates is the O antigen restriction, 
which limits the scope of protection they can offer and 
requires the development of a multi-serotype vaccine to 
10 provide adequate protective coverage in Shigella endemic 
areas. 
SEQUENCE LISTING The type III secretion system (TTSS) is a common 
virulence mechanism in many Gram-negative pathogens. 
This application includes as the Sequence Listing the 
complete contents of the accompanying text file 
"Sequence.txt", created Dec. 7, 2011, containing 17,471 
bytes, hereby incorporated by reference. 
15 Resembling a molecular needle and syringe, the TTSS 
apparatus provides a conduit for the translocation of effector 
proteins from the bacterial cytoplasm to the host cell cyto-
plasm. Residing atop the TTSS needle tip is a tip complex 
composed of IpaB and IpaD sequentially assembled, which 
FIELD OF THE INVENTION 
The invention generally relates to broad based, cross-
protective, O-serotype independent vaccines against Shi-
gella. In particular, the invention provides broadly protec-
tive Shigella vaccines comprising one or more of the type III 
secretion (TTS) apparatus needle proteins IpaD and IpaB, 
and/or the IpaB cognate chaperone protein IpgC, and/or 
chimeric proteins thereof. 
20 is required for pathogenesis. Several studies have reported 
the presence of antibodies against Ipa proteins in serum from 
infected individuals, in subjects immunized with live attenu-
ated organisms during clinical trials and following vaccina-
tion in animal models. The conserved nature of the IpaB and 
25 IpaD and their critical role in pathogenesis make them ideal 
targets for vaccine development. An !pa-based vaccine 
would provide broader coverage across multiple serotypes. 
It would also simplify vaccine production and formulation. 
BACKGROUND OF THE INVENTION 
Shigellosis is a severe diarrheal disease caused by infec-
tion by bacteria of the genus Shigella. Shigellosis is asso-
ciated with high morbidity and mortality rates, particularly 
30 
in the developing world. It is also responsible for long-term 35 
effects on cognitive and physical development in children. 
The global burden has been estimated at more than 160 
million cases per year; the most affected being children 
under 5 years of age living in endemic areas. The causative 
agent can be transmitted from person to person through 40 
fecal-oral contact or through contaminated fomites; inges-
tion of as few as 10 organisms can cause illness in adult 
volunteers. In industrialized countries, Shigella is known to 
be responsible for cases of pediatric diarrhea and to cause 
occasional foodbome outbreaks. Other susceptible groups 45 
include travelers, military personnel and refugees. Addition-
ally, the Centers for Disease Control and Prevention lists 
Shigella as a food safety threat. 
The Shigella genus comprises four different species: 
Shigella dysenteriae, Shigella jlexneri, Shigella sonnei and 50 
Shigella boydii. These organisms are further divided into 
multiple serotypes, based on the structure of the O-polysac-
charide portion of their outer membrane lipopolysaccharide 
(LPS), thereby increasing their antigenic variability. One 
serotype in particular, S. dysenteriae serotype 1, which 55 
produces Shiga toxin, is responsible for the most severe 
infections, including hemolytic uremic syndrome and it is 
the cause of epidemic dysentery. Additionally, serotypes can 
drift during outbreaks, further limiting the efficacy of vac-
cines that are restricted to particular serotypes. The emer- 60 
gence of strains resistant to antimicrobial drugs, including 
ciprofloxacin, currently the first-line antibiotic treatment 
against Shigella infections, heightens the difficulty of con-
trolling this pathogen and makes the development of an 
effective vaccine even more urgent. 65 
Despite being a longstanding priority for the World Health 
Organization, and the progress made in recent years, no 
SUMMARY OF THE INVENTION 
The present invention provides broad-based, protective 0 
antigen-independent vaccines against Shigella and related 
pathogens. The vaccines are advantageously not subject to 0 
antigen restriction and thus may be used to confer protection 
against a wide range of Shigella species and related patho-
gens. The vaccines have been developed using the surface-
exposed proteins at the tip of the type III secretion (TTS) 
apparatus needle from Shigella, as well as a cognate chap-
erone protein. The two TTS apparatus needle tip proteins 
from Shigella are the initial tip protein IpaD and the first 
'translocator') protein IpaB. Within the cytoplasm of Shi-
gella, IpaB forms a complex with its cognant chaperone 
IpgC. For vaccines, recombinant IpaB was prepared with its 
chaperone by co-expression in E. coli and co-purification via 
column chromatography. In addition, IpaB was prepared 
alone by inducing its release from the chaperone using 
various detergents, thereby leaving IpaB for independent 
purification. Thus, the IpaB/IpgC complex, IpaB alone, and 
IpaD were examined as protective antigens by immunizing 
mice intranasally and challenging the mice with S. jlexneri 
and S. sonnei. The challenge results showed that all three of 
these antigen preparations (individually and/or in combina-
tion) were effective in protecting the mice against homolo-
gous S. jlexneri challenge and heterologous (O-serotype 
independent) S. sonnei challenge. This discovery provides a 
significant advancement over the live-attenuated and lipopo-
lysaccaride-based vaccines that are currently being tested. In 
some embodiments, the proteins are advantageously admin-
istered as chimeric proteins which comprise two or more of 
the proteins encompassed in single recombinant protein 
vaccme. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. SDS-PAGE of purified recombinant proteins. 
IpaD (lane 1), IpaB (lane 2) and IpaB/IpgC (lane 3) (5 µg) 
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were subjected to SDS-PAGE and subsequently stained with 
Coomassie Blue R-250. Molecular weight markers (in kDa) 
are on the left. 
FIG. 2. CD spectroscopy of recombinant proteins. (A) 
Far-UV spectra of recombinant proteins were recorded at 5 
10° C. in 10 mM phosphate/citrate buffer at pH 7.2. (B) 
Temperature dependence of the molar ellipticity at 222 nm 
of recombinant proteins was monitored from 10° C. to 90° 
C. at 2.5° C. intervals at a rate of 15° C./h. Error bars have 
been omitted for clarity; uncertainty was less than 5% (n=3). 10 
FIG. 3. Serum antibody responses to IpaB, IpaD and 
dmLT. Mice were immunized on day 0, 14 and 28 (arrows). 
Serum IgG antibodies specific for IpaB (A), IpaD (B) and 
dmLT (C) were measured by ELISA. Data represents mean 15 
titers (EU ml-l)±SE from 10 mice per group. * P<0.05 
vaccinated vs. PBS controls. 
FIG. 4. Antibody secreting cells in spleen and bone 
marrow. Spleens (A) and bone marrows (B) were collected 
on day 56. Single cell suspensions from 5 mice per group 20 
were stimulated in vitro with IpaB or IpaD. IgG and IgA 
ASC were measured by ELI Spot. Bars represent mean ASC 
per 106 cells+SD from replicate wells. * P<0.05 vs. PBS 
control mice. 
FIG. 5. Fecal IgA responses to IpaB, IpaD and dmLT. 25 
Mice were immunized on day 0, 14 and 28 (arrows). IgA 
specific for IpaB (A), IpaD (B) and dmLT (C) was measured 
by ELISA in stool supernatants. Data represents mean titers 
(EU ml-l)±SE from 10 mice per group, except for day 56, 
which included 5 mice in each group. * P<0.05 vs. PBS 30 
control mice. 
FIG. 6. Antibody secreting cells in nasal tissue. Nasal 
associated lymphocyte tissue was collected on day 56 and 
single cell suspensions were prepared from 5 mice per 35 
group. IgG and IgA ASC specific IpaB and IpaD were 
measured by ELIS pot. Bars represent mean±SD per 106 
cells from replicate wells. * P<0.05 vs. PBS control mice. 
FIG. 7. IFN-y secreting cells. Spleens were collected on 
day 56 from 5 mice per group. Single cell suspensions were 40 
prepared and stimulated with 5 µg/ml IpaB or IpaD for 48 h. 
Results are shown as IFN-y SFC per 106 cells+SD from 
quadruple wells * P<0.05 vs. mice that received PBS. 
FIG. 8. Protection against Shigella ssp. in a lethal pul-
monary challenge. Mice were challenged on day 56 after the 45 
first immunization. Two dosage levels were used for each 
strain: 6x107 CFU of S. jlexneri, corresponding to -11 
MLD50, and 1.lx108 CFU of S. sonnei (-5 MLD50) (A); 
1.3x108 CFU of S. jlexneri, corresponding to -24 MLD50 
and 2x108 CFU of S. sonnei (-9 MLD50) (B). Data repre- 50 
sent survival curves from 10 mice per group. 
FIGS. 9A and B. Protective efficacy of IpaB/D proteins 
against S. jlexneri pulmonary challenge. A, Percent survival; 
B, vaccine efficacy. 
FIG. 10. Protective efficacy oflpaB/D proteins against S. 55 
sonnei pulmonary challenge. A, Percent survival; B, vaccine 
efficacy. 
FIG. 11. SDS-PAGE of IpaD-IpaD chimeric protein. 
FIG. 12A-D. Amino acid sequence of full length proteins 
for A, IpaB (SEQ ID NO: 1); B, IpaD (SEQ ID NO: 2); C, 60 
IpgC (SEQ ID NO: 3); D, fusion protein of IpaD and IpaB 
(SEQ ID NO: 4). 
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bodies in: A, lungs; B, Peyer's patches (PP); C, nasal 
associated lymphoid tissue (NALT); D, spleen; and E, bone 
marrow. 
FIG. 15A-C. A, IFN-y secreting cells; B, cytokine secre-
tion; and C, IL-17 secretion. 
FIG. 16. Detergent effects on IpaD/B fusion protein 
structure measured by circular dichroism (CD). 
FIG. 17. CD thermal melts of DB fusion protein. 
FIG. 18A-D. CD profiles before and after heating to 90° 
C. A, IpaD+PpaB in 0.5% OPOE; B, IpaB/B fusion in 0.5% 
OPOE; C, BIB fusion in PBS; D, IpaB/B fusion in LDAO. 
FIGS. 19A and B. Serum and mucosa! antibody responses 
to IpaB. Serum IgG GMTs (A) and mucosa! IgA titers in 
pooled tears (B) are shown for each immunization group for 
each subsequent collection. BL-1, pre-immune titer; BL-2, 
post 1 dose; BL-3, post 2 doses; and BL-4, post 3 doses. 
FIGS. 20A and B. Serum and mucosa! antibody responses 
to IpaD. Serum IgG GMTs (A) and mucosa! IgA titers in 
pooled tears (B) are shown for each immunization group for 
each subsequent collection. BL-1, pre-immune titer; BL-2, 
post 1 dose; BL-3, post 2 doses; and BL-4, post 3 doses. 
FIGS. 21A and B. Serum and mucosa! antibody responses 
to dmLT. Serum IgG GMTs (A) and mucosa! IgA titers in 
pooled tears (B) are shown for each immunization group for 
each subsequent collection. BL-1, pre-immune titer; BL-2, 
post 1 dose; BL-3, post 2 doses; and BL-4, post 3 doses. 
FIGS. 22A and B. Serum and mucosa! antibody responses 
to S. jlexneri 2a LPS. Serum IgG GMTs (A) and mucosa! 
IgA titers in pooled tears (B) are shown for each immuni-
zation group for each subsequent collection. BL-1, pre-
immune titer; BL-2, post 1 dose; BL-3, post 2 doses; and 
BL-4, post 3 doses. 
FIG. 23. Schematic of challenge experiment. 
FIG. 24A-C. Kinetics of serum A, IpaB-, B, IpaD-, and C, 
dmLT-specific IgG antibodies and stool IpaB-, IpaD-, and 
dmLT-specific IgA antibodies. Mice were immunized with 
IpaB and IpaD, along with dmLT on days 0, 14 and 28 (see 
FIG. 23). Serum IgG and stool IgA antibody titers were 
measured by ELISA. Data represent mean titers±SEM of 
individual samples from each group. 
FIG. 25A-C. A, IpaB-, B, IpaD- and C, dmLT-specific IgG 
and IgAASCs in lungs. Mice were immunized as described 
in Example 4. Lungs were collected from 5 mice in each 
group on day 5 and single cell suspensions prepared. Viable 
lymphocytes were separated using Lympholyte density gra-
dient. The frequencies of IgA and IgG ASC were measured 
by ELISpot. Results are shown as mean IgG (white bars) or 
IgA (black bars) IpaB-, IpaD- and dmLT-specific ASCs per 
106 cells+SEM from wells in triplicate (lungs for each group 
were pooled). 
FIG. 26A-C. Spleen A, IpaB-, B, IpaD- and C, dmLT-
specific IgG and IgA ASCs. Mice were immunized as 
described in Example 4. Spleens were collected on day 56 
from 5 mice in each group and single cell suspensions 
prepared. The frequencies of IgA and IgG ASC were mea-
sured by ELISpot. Results are shown as mean IgG (white 
bars) or IgA (black bars) IpaB-, IpaD- and dmLT-specific 
ASCs per 106 cells+SEM from quadruplicate wells. 
FIG. 27A-C. Bone Marrow A, IpaB-, B, IpaD- and C, 
dmLT-specific IgG and IgAASCs. Mice were immunized as 
described in FIG. 4. BM was collected on day 56 from 5 
mice in each group and single cell suspensions prepared. 
The frequencies of IgA and IgG ASC were measured by 
FIGS. 13A and B. Serum IgG levels in mice at the 
indicated intervals. A, IgG reactive with IpaB; B, IgG 
reactive with IpaD. 
FIG. 14A-E. Levels of IgG and IgA in response to DB 
fusion administration as detected by IpaB and IpaD anti-
65 ELIS pot. Results are shown as mean IgG (white bars) or IgA 
(black bars) IpaB-, IpaD- and dmLT-specific ASCs per 106 
cells+SEM from triplicate wells. 
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FIG. 28A-F. IpaB and IpaD-specific Thl cytokine secre-
tion by spleen cells. Mice were innnunized as described in 
Example 4. Spleens were collected on day 56 and single cell 
suspensions prepared. Cells were incubated for 48 h in the 
presence oflpaB (A, C, E) and IpaD (B, D, F). Supematants 5 
were tested for the presence of cytokines using a microarray 
multiplex assay (MSD, Mouse Thl/Th2 9-Plex). Results are 
shown as mean IFN-y (A-B), TNF-a (C-D) and IL-2 (E-F) 
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FIG. 36A-C. Spleen A, IpaB-, B, IpaD- and C, dmLT-
specific IgG and IgA ASCs. Mice were innnunized as 
described for FIG. 23. Spleens were collected on day 35 
from 5 mice in each group and single cell suspensions 
prepared. The frequencies of IgA and IgG ASC were mea-
sured by ELISpot. Results are shown as mean IgG (white 
bars) or IgA (black bars) IpaB-, IpaD- and dmLT-specific 
ASCs per 106 cells+SEM from quadruplicate wells. 
FIG. 37 A-C. A, IpaB-, B, IpaD- and C, dmLT-specific IgG in pg/ml+SEM from triplicate wells. Dashed line represents 
average baseline secretion by unstimulated cells from all 
groups. 
FIG. 29A-D. IpaB and IpaD-induced pro-inflarmnatory 
cytokine production in spleen cells. Mice were innnunized 
as described in FIG. 4. Spleens were obtained from 5 mice 
in each group on day 56. Single cell suspensions were 
prepared. Cells were incubated for 48 hours with IpaB (A, 
C), IpaD (B, D) and supernatants tested for cytokine pro-
duction as described in FIG. 23, using a multiarray MSD, 
Mouse Thl/Th2 9-Plex Assay. Results are shown as mean 
IL-12 (AB) and IL-1 ~ (C-D) in pg/ml+SEM from triplicate 
wells. Dashed line represents average baseline cytokine 
secretion by unstimulated cells from all groups. 
10 and IgA in bronchoalveolar lavage (BAL). Mice were 
innnunized as described for FIG. 23. BAL fluid was col-
lected on day 35 from 5 mice in each group and supernatant 
was removed and stored at -20° C. until analysis. IgG and 
IgA titers were measured by ELISA. Results are shown as 
15 mean IpaB-, IpaD- and dmLT-specific IgG (white bars) or 
IgA (black bars) titers+SEM. 
FIG. 38. Protective efficacy against S. jlexneri. Mice were 
innnunized i.d. as described above for FIG. 23. Challenge 
was performed on day 56 after innnunization. The animals 
20 received 5.8xl07 CFU of S.jlexneri 2a in 30 µI administered 
i.n. Challenge was performed under anesthesia. Mice were 
monitored for 14 days. Health scores and body weight were 
recorded daily. Data represent survival curves from 10 mice 
FIG. 30A-F. IpaB and IpaD induced Th2 and anti-inflam-
matory cytokine secretion by splenocytes. Mice were innnu- 25 
nized as described in FIG. 4. Spleens were obtained from 5 
mice in each group on day 56. Single cell suspensions were 
prepared and cells were incubated for 48 hours with IpaB 
(A, C), IpaD (B, D). Supematants were tested for secretion 
per group. 
FIGS. 39A and B. Protective efficacy against S. jlexneri 
and S. sonnei. Mice were immunized as described for FIG. 
23. Challenge was performed on day 56 after innnunization. 
(A) 10 animals per group received 5.4x107 CFU of S. 
flexneri 2a and (B) 10 animals per group received 1.35xl08 
of cytokines using a multiarray MSD sandwich Mouse 
Thl/Th2 9-Plex Assay. Results are shown as mean IL-10 
(A-B), IL-4 (C-D) and IL-5 (E-F) in pg/ml+SEM from 
triplicate wells. Dashed line represents average baseline 
cytokine secretion by unstimulated cells from all groups. 
FIG. 31. Schematic of challenge experiment. 
FIG. 32A-C. Kinetics of serum A, IpaB-, B, IpaD-, and C, 
dmLT-specific IgG (Experiment 2). Mice were innnunized 
with IpaB and IpaD, along with dmLT on days 0, 14 and 28 
as described above. Serum IgG and stool IgA antibody titers 
were measured by ELISA. Data represent pool titers from 
each group. 
FIG. 33A-C. A, IpaB-, B, IpaD- and C, dmLT-specific IgG 
and IgAASCs in lungs. Mice were innnunized as described 
in FIG. 12. Lungs were collected on day 35 post-primary 
immunization from 5 mice in each group on day 35 and 
single cell suspensions prepared. Lymphocytes were sepa-
rated using Lympholyte density gradient. The frequencies of 
IgA and IgG ASC were measured by ELISpot. Results are 
shown as mean IgG (white bars) or IgA (black bars) IpaB-, 
IpaD- and dmLT-specific ASCs per 106 cells+SEM from 
triplicate wells (lungs for each group were pooled). 
FIG. 34A-C. NALT A, IpaB-, B, IpaD- and C, dmLT-
specific IgG and IgA ASCs. Mice were innnunized as 
described in FIG. 23. Nasal tissues were collected on day 35 
from 5 mice in each group and single cell suspensions 
prepared. The frequencies of IgA and IgG ASC were mea-
sured by ELISpot. Results are shown as mean IgG (white 
bars) or IgA (black bars) IpaB-, IpaD- and dmLT-specific 
ASCs per 106 cells+SEM from triplicate wells. 
30 CFU S. sonnei. The organisms were administered in 30 µI 
via i.n. Mice were monitored for 14 days. Health scores and 
body weight were recorded on daily basis. Data represent 
survival curves from 10 mice per group. 
FIG. 40. Progression of disease following challenge with 
35 WT S. flexneri 2a 2457T. 
FIGS. 41A and B. Serum and mucosa! antibody responses 
to IpaB. Serum IgG GMTs (A) and mucosa! IgA titers in 
pooled tears (B) are shown for each innnunization group for 
each subsequent collection. BL-1, pre-innnune titer; BL-2, 
40 post 1 dose; BL-3, post 2 doses; and BL-4, post 3 doses. 
FIGS. 42A and B. Serum and mucosa! antibody responses 
to IpaD. Serum IgG GMTs (A) and mucosa! IgA titers in 
pooled tears (B) are shown for each innnunization group for 
each subsequent collection. BL-1, pre-innnune titer; BL-2, 
45 post 1 dose; BL-3, post 2 doses; and BL-4, post 3 doses. 
FIGS. 43A and B. Serum and mucosa! antibody responses 
to dmLT. Serum IgG GMTs (A) and mucosa! IgA titers in 
pooled tears (B) are shown for each innnunization group for 
each subsequent collection. BL-1, pre-innnune titer; BL-2, 
50 post 1 dose; BL-3, post 2 doses; and BL-4, post 3 doses. 
FIGS. 44A and B. Serum and mucosa! antibody responses 
to IpaB. Serum IgG GMTs (A) and mucosa! IgA titers in 
pooled tears (B) are shown for each innnunization group for 
each subsequent collection. BL-1, pre-innnune titer; BL-2, 
55 post 1 dose; BL-3, post 2 doses; and BL-4, post 3 doses. 
FIG. 45. Serum IgG response of piglets against Ipa 
vaccine administered IS, SL and ID+SL. 
FIG. 46. IgA response of piglets against Ipa vaccine 
administered IS, SL and IS+SL. 
FIG. 35A-C. Peyer's patches A, IpaB-, B, IpaD- and C, 60 
dmLT-specific IgG and IgAASCs. Mice were innnunized as 
described in FIG. 23. Peyer's patches were collected on day 
FIGS. 47A and B. Protective efficacy of the DB fusion in 
mice. A, when challenged with S jlexneri; B, when chal-
lenged with S sonneri. 
35 from 5 mice in each group and single cell suspensions 
prepared. The frequencies of IgG and IgA ASCs were 
measured by ELISpot. Results are shown as mean IgG 65 
(white bars) or IgA (black bars) IpaB-, IpaD- and dmLT-
specific ASCs per 106 cells+SEM from triplicate wells. 
DETAILED DESCRIPTION 
The immunogenicity of the Shigella proteins IpaB, IpaD 
and IpgC administered alone or combined (e.g. as an IpaB/ 
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IpgC complex), have been shown to provide protective 
immunity to mammals against the otherwise serious conse-
quences of exposure to and infection by Shigella. Signifi-
cantly, the administration of these proteins afforded protec-
tion in an O-independent manner, i.e. protection was not 5 
limited to a single O-type. Thus, vaccines formulated from 
the proteins may be used to protect recipients from disease 
caused by a broad range of Shigella and related organisms. 
In some embodiments, the proteins are administered 
together with a mucosa! adjuvant such as the double mutant 10 
heat-labile toxin (dmLT) from enterotoxigenic E. coli. 
The proteins which may be used in the practice of the 
invention include IpaB, IpaD and IpgC, administered alone 
or in various forms and combinations as described herein. 
The full length sequences of each of these proteins are 15 
provided in FIGS. 12A, Band C, respectively. The phrase(s) 
IpaB, IpaD and IpgC protein(s) as used herein refer to both 
the full length proteins as depicted in the figures, and also to 
antigenic regions thereof. By an "antigenic region" we mean 
a foreshortened or truncated version or form of the protein 20 
which elicits the same or a comparable level of protection as 
the full length protein from which it is taken, a comparable 
level being in the range of at least about 50, 55, 60, 65, 70, 
75, 80, 85, 90, 95, or even 100% (or more) of the protective 
activity of the parent, full-length molecule. An antigenic 25 
region may be a shorter protein ( e.g. containing more than 
about 250 amino acids), a polypeptide ( e.g. containing less 
than about 250 amino acids but more than about 100 amino 
acids), or a peptide ( e.g. containing less than about 100 
amino acids). Those of skill in the art will recognize that the 30 
"definitions" of protein, polypeptide and peptide may vary 
within the art, and may overlap in meaning, and are often 
used interchangeably. 
The proteins, polypeptides or peptides which may be used 
in the practice of the invention include IpaB, IpaD and IpgC, 35 
and variants or derivatives thereof which have about at least 
about 50, 55, 60, 65, 70, 75, 80, 85, or 90% identity to the 
sequences presented herein, and preferably the level of 
identity is at least about 92, 93, 94, 95, 96, 97, 98 or 99%. 
Those of skill in the art are familiar with methods and 40 
software programs for sequence comparison to determine 
identity. 
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In some embodiments of the invention, the proteins, 
polypeptides or peptides that are used in the vaccine are 
chimeric proteins. By a "chimeric protein" we mean a 
protein that is translated from a single, contiguous nucleic 
acid molecule, and which comprises sequences from at least 
two different proteins or antigenic regions thereof. For 
example, a chimera of the invention may include two or 
more of IpaB and/or IpaD and/or IpgC, or antigenic regions 
of two or more of these. Typically, the individual sequences 
are joined via a linker or spacer sequence of e.g. from about 
2 to about 20 amino acids, usually from about 2 to about 10 
amino acids. The amino acids in linking sequences are 
typically uncharged and the linker sequence usually does not 
exhibit secondary or tertiary structure, but does allow the 
fused protein segments to adopt functional secondary, ter-
tiary, etc. conformations. 
The present invention provides compositions for use in 
eliciting an immune response and/or vaccinating an indi-
vidual against Shigella, or against disease symptoms caused 
by Shigella infection, and/or infection by related organisms. 
The compositions include one or more substantially purified 
proteins, polypeptides or antigenic regions thereof as 
described herein, or substantially purified nucleic acid 
sequences (e.g. DNA cDNA, RNA, etc.) encoding such 
proteins, polypeptides or antigenic regions thereof, and a 
pharmacologically suitable carrier. By "substantially puri-
fied" we mean that the molecule is largely free of other 
organic molecules, cellular debris, solvents, etc. when tested 
using standard techniques known to those of skill in the art 
( e.g. gel electrophoresis, colunm chromatography, sequenc-
ing, mass spectroscopy, etc.). For example, the molecule is 
generally at least about 50, 55, 60, 65, 70, or 75% pure, and 
preferably is at least about 80, 85, 90, 95% or more pure ( e.g. 
96, 97, 98, 99 or even 100% pure). The preparation of 
proteins, polypeptides, and peptides as described herein is 
well-known to those in the art, and includes, for example, 
recombinant preparation; isolation from a natural source; 
chemical synthesis; etc. The purification of proteinaceous 
materials is also known, and new improved methods that are 
advantageous for the proteins utilized in the practice of the 
invention are described in the Examples section below. 
The preparation of compositions for use as vaccines is 
well known to those of skill in the art. Typically, such 
The invention also encompasses the use of nucleic acids 
encoding the proteins/polypeptides/peptides described 
herein, i.e. nucleic acid vaccines are also contemplated. 
Those of skill in the art are aware of the many protocols for 
preparing and administering nucleic acid vaccines, such as 
those described in issued U.S. Pat. Nos. 7,927,870 and 
7,094,410, the complete contents of which is hereby incor-
porated by referenced in entirety. 
45 compositions are prepared either as liquid solutions or 
suspensions, however solid forms such as tablets, pills, 
powders and the like are also contemplated. Solid forms 
suitable for solution in, or suspension in, liquids prior to 
administration may also be prepared ( e.g. lyophilized, 
Those of skill in the art will appreciate that the genetic 
code is redundant and that many sequences may encode a 
given amino acid sequence. All nucleic acid sequences ( e.g. 
DNA, RNA, cDNA, DNA/RNA hybrids, etc.) which suc-
cessfully encode and express the proteins/polypeptides/pep-
tides described herein, in a manner that results in protection 
50 freeze-dried forms, etc.). The preparation may also be emul-
sified. The active ingredients may be mixed with excipients 
which are pharmaceutically acceptable and compatible with 
the active ingredients. Suitable excipients are, for example, 
water, saline, dextrose, glycerol, ethanol and the like, or 
55 combinations thereof. In addition, the composition may 
contain minor amounts of auxiliary substances such as 
wetting or emulsifying agents, pH buffering agents, and the 
like. If it is desired to administer an oral form of the 
of a subject to whom the vaccine is administered, also as 
described herein, may be used in the practice of the inven-
tion. Also encompassed are vectors which contain such 
nucleic acid sequences ( e.g. plasmids, cosmids, various 60 
expression vectors, etc.), and host cells such as bacteria, 
insect cells, etc., which comprise the nucleic acid sequences 
and/or the vectors. Such vectors typically include one or 
more expressible gene sequences encoding one or more or 
the proteins/polypeptides/peptides of interest, which may be 65 
a chimera, operably linked to at least one transcription 
element (e.g. a promoter) that drives expression of the gene. 
composition, various thickeners, flavorings, diluents, emul-
sifiers, dispersing aids or binders and the like may be added. 
The composition of the present invention may contain any 
such additional ingredients so as to provide the composition 
in a form suitable for administration. The final amount of 
protein, polypeptide or peptide ( or encoding nucleic acids) 
in the formulations may vary. However, in general, the 
amount in the formulations will be from about 1 to about 
99%. 
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In addition, the composition may contain adjuvants, many 
of which are known in the art. For example, adjuvants 
suitable for use in the invention include but are not limited 
to: bacterial or microbial derivatives such as non-toxic 
derivatives of enterobacterial lipopolysaccharide (LPS), 
Lipid A derivatives, immunostimulatory oligonucleotides 
and ADP-ribosylating toxins and detoxified derivatives 
thereof. Non-toxic derivatives of LPS include monophos-
phoryl lipid A (MPL) and 3-O-deacylated MPL (3dMPL). 
3dMPL is a mixture of 3 de-O-acylated monophosphoryl 
lipid A with 4, 5 or 6 acylated chains. A preferred "small 
particle" form of 3 de-O-acylated monophosphoryl lipid A. 
Other non-toxic LPS derivatives include monophosphoryl 
lipid A mimics, such as aminoalkyl glucosaminide phos-
phate derivatives e.g. RC-529. Lipid A derivatives include 
derivatives of lipid A from Escherichia coli such as 
OM-174. Immunostimulatory oligonucleotides suitable for 
use as adjuvants in the invention include nucleotide 
sequences containing a CpG motif (a dinucleotide sequence 
containing an unmethylated cytosine linked by a phosphate 
bond to a guano sine). Double-stranded RN As and oligo-
nucleotides containing palindromic or poly (dG) sequences 
have also been shown to be immunostimulatory. The CpG's 
can include nucleotide modifications/analogs such as phos-
phorothioate modifications and can be double-stranded or 
single-stranded. e.g. replacement of guanosine with 2'-de-
oxy-7-deazaguanosine. The CpG sequence may include, for 
example, the motif GTCGTT or TTCGTT. The CpG 
sequence may be specific for inducing a Thi immune 
response, such as a CpG-A ODN, or it may be more specific 
for inducing a B cell response, such a CpG-B ODN. CpG-A 
and CpG-B ODNs. Preferably, the CpG is a CpG-A ODN. 
Preferably, the CpG oligonucleotide is constructed so that 
the 5' end is accessible for receptor recognition. Optionally, 
two CpG oligonucleotide sequences may be attached at their 
3' ends to form "immunomers". 
Bacterial ADP-ribosylating toxins and detoxified deriva-
tives thereof may be used as adjuvants in the invention. 
Preferably, the protein is derived from E. coli (e.g. E. coli 
heat labile enterotoxin "LT"), cholera ("CT"), or pertussis 
("PT"). The use of detoxified ADP-ribosylating toxins as 
mucosa! adjuvants and as parenteral adjuvants are known. 
The toxin or toxoid is preferably in the form of a holotoxin, 
comprising both A and B subunits. Preferably, the A subunit 
contains a detoxifying mutation; preferably the B subunit is 
not mutated. Preferably, the adjuvant is a detoxified LT 
mutant such as LT-K63, LT-R72, and LT-G192. The use of 
ADP-ribosylating toxins and detoxified derivatives thereof, 
particularly LT-K63 and LT-R72, is known. Such adjuvants 
are described, for example, in issued U.S. Pat. No. 8,039,007 
(the complete contents of which is hereby incorporated by 
reference in entirety). Various interleukins may also be used 
as adjuvants to increase the immune response in a subject. 
In preferred embodiments, the adjuvant is a mucosa! adju-
vant such as, for example, the double mutant heat-labile 
toxin ( dmLT) from enterotoxigenic E. coli. 
The vaccine compositions (preparations) of the present 
invention may be administered by any of the many suitable 
means which are well known to those of skill in the art, 
including but not limited to by injection, inhalation, orally, 
intranasally, topically, etc. In preferred embodiments, the 
mode of administration is intranasal. In addition, the com-
positions may be administered in conjunction with or in a 
composition which contains other antigens of interest. In 
other words, they may be administered as a component of a 
multivalent vaccine which also contains antigens against 
10 
other related or non-related infectious diseases, especially 
childhood diseases, such as polio, whooping cough, tetanus, 
diphtheria, etc. 
Recipients of the vaccine of the invention are generally 
5 mammals, frequently humans, but this need not always be 
the case. Veterinary applications are also contemplated. The 
vaccine are often administered as or together with so-called 
"child hood" vaccines. Thus, the recipients are preferably 
human children who may be infants ( e.g. up to about 1 hear 
10 of age), toddlers (e.g. up to about 2 years of age), or older, 
and administration may be carried out as a series of initial 
inoculations followed by booster doses at suitable intervals, 
e.g. monthly, or every 6-months, or yearly, etc. as necessary 
to provide protection. Thereafter, or in the case of adults who 
15 have not previously been vaccinated, the vaccines may be 
administered as necessary to result in a protective immune 
response, and subjects may be re-boosted e.g. about every 10 
years throughout adult life. 
Vaccine recipients may have never been exposed to 
20 Shigella, or may have been exposed or suspected of having 
been exposed but be asymptomatic, or may have actual 
symptoms of shigellosis, and still benefit from administra-
tion of the vaccine. Vaccine administration may prevent 
disease symptoms entirely, or may lessen or decrease disease 
25 symptoms, the latter outcome being, while not being ideal, 
still better than experiencing full-blown disease symptoms. 
The amount of protein that is administered per dose of 
vaccine is typically in the range of from about 1 to about 
1000 µg/kg, and is usually in the range of from about 0.02 
30 to about 20 µg/kg of body weight of the recipient. Those of 
skill in the art will recognize that the precise dosage may 
vary from situation to situation and from patient to patient, 
depending on e.g. age, gender, overall health, various 
genetic factors, and other variables known to those of skill 
35 in the art. Dosages are typically determined e.g. in the course 
of animal and/or human clinical trials as conducted by 
skilled medical personnel, e.g. physicians. 
The vaccines and immunogenic compositions of the 
invention may be used to provide immune protection against 
40 various Shigella species in an O-independent manner, 
examples of which include but are not limited to: S.jlexneri, 
S. sonnei, Shigella dysenteriae, and Shigella boydii. 
In addition, the compositions may be used to vaccinate or 
elicit and immune response in subject against disease caus-
45 ing pathogens that are related to Shigella, examples of which 
include but are not limited to enteroinvasive E. coli and 
Salmonella enterica serovars Typhi, Paratyphi A & B, 
Typhimurium and Enteritidis. 
Administration of the compositions of the invention 
50 results in the production of a protective immune response in 
subjects who receive the compositions, frequently by the 
elicitation of antibody production against the administered 
antigens. Such antibodies are also encompassed by the 
invention, for example, those generated using laboratory 
55 techniques in experimental animals, or using cell culture, or 
by chemical syntheses, etc. Such antibodies may be poly-
clonal or monoclonal, and may be specific for the antigens 
(reacting with no other antigens) or selective for the antigens 
(reacting more strongly or preferably with the antigens, 
60 compared to other antigens). The antibodies may be multi-
valent. The antibodies may be used for research and/or 
diagnostic purposes, or alternatively, for treatment, espe-
cially of individuals who are infected with Shigella. 
The invention provides methods of vaccinating, or, alter-
65 natively, of eliciting an immune response, in a subject in 
need thereof. The method generally involves identifying a 
suitable subject, and administering the composition as 
US 9,492,523 B2 
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described herein. The method may also encompass follow-
up of administration, e.g. by assessing the production of 
protective antibodies by the subject, or the presence ( or lack 
thereof) of disease symptoms, etc. The immune response 
that is elicited may be of any type, i.e. any type of antibody 5 
may be produced in response to administration, and cell-
mediated immunity may also be elicited. 
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IpaD with Isopropyl-~-D-thio-galactoside (IPTG). The bac-
teria were grown an additional three hours to allow protein 
expression to occur. Alternatively, a starter culture of 100 ml 
was used to inoculate a 5- or IO-liter fermentor vessel 
containing TB media. After growing overnight (16 hours), 
the bacteria were induced and allowed to express protein for 
three hours. The bacteria were collected by centrifugation, 
resuspended in binding buffer (see below for recipe), and 
lysed by microfluidization. This suspension was clarified by 
The foregoing Examples serve to illustrate exemplary 
aspects of the invention, but should not be interpreted as 
limiting in any way. 
EXAMPLES 
Example 1 
10 centrifugation and was loaded onto a nickel charged immo-
bilized metal affinity column (IMAC). The colunm (5 ml) 
was washed with 10 bed volumes each of binding and wash 
buffers and then subjected to a gradient of0% to 40% elution 
buffer. Peak fractions were combined, buffer exchanged into 
A Cross-Protective TTSA-Protein Shigella Vaccine 
15 10 mM Tris-HCI pH 7.5, 10 mM NaCl and loaded onto a 
Q-Sephadex anion exchange colunm (5 ml). The IpaD was 
eluted via a gradient from 0-16% IM NaCl in 10 mM Tris 
pH 7.5 over 15 colunm volumes. The peak fractions were 
combined and dialyzed against PBS. Pure protein was stored 
Shigella ssp. are food and water-borne pathogens that 
cause severe diarrheal and dysenteric disease associated 
with high morbidity and mortality. Individuals most often 
affected are children under 5 years of age in the developing 
world. The existence of multiple Shigella serotypes and the 
heterogenic distribution of pathogenic strains as well as 
emerging antibiotic resistance require the development of a 
broadly protective vaccine. All Shigella ssp. utilize a type III 25 
secretion system (TTSS) to initiate infection. The type III 
secretion apparatus (TTSA) is the molecular needle and 
syringe that forms the energized conduit between the bac-
terial cytoplasm and the host cell to transport effector 
proteins that manipulate cellular processes to benefit the 30 
pathogen. IpaB and IpaD form a tip complex atop the TTSA 
needle and are required for pathogenesis. Because they are 
common to all virulent Shigella, they are ideal candidate 
antigens for a subunit-based, broad-spectrum vaccine. We 
examined the immunogenicity and protective efficacy of 35 
IpaB and IpaD, alone or combined, co-administered with a 
double mutant heat-labile toxin (dmLT) from E. coli as a 
mucosa! adjuvant in a mouse model of intranasal immuni-
zation and pulmonary challenge. Robust systemic and 
mucosa! antibody and T cell-mediated immunity were 40 
induced against both proteins, particularly IpaB. Mice 
immunized with IpaB alone or combined with IpaD, in the 
presence of dmLT, were fully protected against lethal pul-
monary infection with S. jlexneri and S. sonnei. We show 
that Shigella TTSA IpaB and IpaD are promising antigens 45 
for the development of a cross-protective Shigella vaccines. 
Materials and Methods 
Protein purification materials. Plasmids and competent E. 
coli were obtained from Novagen (Madison, Wis.). Metal 
affinity colunms, Q-Sephadex, Butyl Sepharose and HiLoad 
16/60 Superdex 200 preparative grade colunms were 
obtained from GE Healthcare (Piscataway, N.J.). n-octyl-
polyoxyethylene (OPOE) was obtained from Alexis Bio-
chemicals (Lausen, Switzerland). All other chemicals were 
reagent grade. 
The gene encoding IpaD was copied by PCR from the 
virulence plasmid of Shigella jlexneri 2457T (accession 
number 104117). The PCR fragment was digested with the 
restriction enzymes Ndel and BamHI and ligated into Ndel/ 
BamHI digested pET15b from Novagen. The ligation prod-
uct was used to transform NovaB!ue E. coli. Transformants 
were screened for the proper insert and subjected to double 
stranded sequencing. A plasmid containing the correct 
sequence was transformed into BL21 (DE3) E. coli (Nova-
gen). This strain was used to inoculate LB media containing 
ampicillin. The bacteria were grown to an absorbance at 600 
of about 0.6 at which time they were induced to over express 
20 at -80° C. 
The gene encoding IpaB was copied by PCR from the 
virulence plasmid of Shigella jlexneri 2457T (accession 
number 104117). The PCR fragment was digested with the 
restriction enzymes Ndel and BamHI and ligated into Ndel/ 
BamHI digested pET15b from Novagen. The ligation prod-
uct was used to transform NovaB!ue E. coli. Transformants 
were screened for the proper insert and subjected to double 
stranded sequencing. The gene encoding IpgC was copied 
by PCR from the virulence plasmid of Shigella jlexneri 
2457T ( accession number 104117). The PCR fragment was 
digested with the restriction enzymes Ndel and Xhol and 
ligated into NdeI/XhoI digested pACYCDuet-1 from Nova-
gen. The ligation product was used to transform NovaB!ue 
E. coli. Transformants were screened for the proper insert 
and subjected to double stranded sequencing. A plasmid 
containing the correct sequence for IpaB and a plasmid 
containing the correct sequence for IpgC were transformed 
into Tuner (DE3) E. coli (Novagen). This strain was used to 
inoculate LB media containing ampicillin and chloram-
phenicol. The bacteria were grown to an absorbance at 600 
of about 0.6 at which time they were induced to over express 
IpaB/IpgC with Isopropyl-~-D-thio-galactoside (IPTG). The 
bacteria were grown an additional three hours to allow 
protein expression to occur. Alternatively, a starter culture of 
100 ml was used to inoculate a 5- or IO-liter fermentor 
vessel containing TB media. After growing overnight (16 
hours), the bacteria were induced and allowed to express 
protein for three hours. The bacteria were collected by 
centrifugation, resuspended in binding buffer (see below for 
50 recipe), and lysed by microfluidization. This suspension was 
clarified by centrifugation and was loaded onto a nickel 
charged immobilized metal affinity column (IMAC). The 
column (5 ml) was washed with 10 bed volumes each of 
binding and wash buffers and then subjected to a gradient of 
55 0% to 40% elution buffer. Peak fractions were collected, the 
buffer exchanged into IM ammonium sulfate in 50 mM 
sodium phosphate pH 7 .0 and loaded onto a Butyl Sepharose 
High Performance colunm (5 ml) with a linear gradient from 
IM ammonium sulfate in 50 mM sodium phosphate pH 7.0 
60 to 50 mM sodium phosphate. For preparation of His-tag 
IpaB, the !MAC-bound protein complex was incubated 
overnight in the presence of 1 % OPOE. The chaperone was 
removed in the flow through and subsequent wash steps. 
His-tag IpaB was eluted in the presence of OPOE to main-
65 tain the protein in a soluble form. His-tag IpaB was then 
further purified using size exclusion chromatography using 
a HiLoad 16/60 Superdex 200 Prep Grade column. All 
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proteins were concentrated by ultrafiltration and dialyzed 
into PBS pH 7.2. Protein concentrations were determined 
via absorbance at 280 nm using extinction coefficients based 
on the amino acid composition of each protein. 
Buffers that were utilized are listed below: 
4x Charge Buffer: 500 ml 
200 mM NiSO4 52.56 g 
8x Binding Buffer: !Liter 
40 mM Imidazole 
4M NaCl 
160 mM Tris 
Mix together and pH to 7.9 with HCI 
8x Wash Buffer: 500 mL 
480 mM Imidazole 
4M NaCl 
160 mM Tris 
Mix together and pH to 7.9 with HCI 
2.72 g 
237 g 
19.36 
16.3 g 
117 g 
19.68 
lX- 50 mM 
lX- 5 mM 
500 mM 
20 mM 
lX - 60 mM 
500 mM 
20 mM 
IF USING UREA drop the imidazole to 20 mM ... 8X = 160 
4x Elution Buffer: 500 mL 
4M Imidazole 136 g lX-lM 
2M NaCl 58.44 .SM 
80 mM Tris 4.84 20mM 
Mix together and pH to 7.9 with HCI 
4x Strip Buffer: 500 mL 
0.4M EDTA 74.4 g lX- 100 mM 
2MNaCl 58.44 500 mM 
80 mM Tris 4.84 20mM 
Mix together. Add NaOH pellets to get pH to 8.0 so that EDTA will dissolve. Then adjust 
pH to 7.9. 
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phate buffered saline (PBS). Colony-forming units (CFU) of 
each challenge dose were determined by plating serial 
dilutions of the culture on Congo Red agar plates. The 
mouse lethal dose 50% (MLD50) for the challenge strains 
5 were calculated by the method of Reed and Muench and 
determined to be -5.4xl06 CFU for S.jlexneri and 1.2x107 
CFU for S. sonnei. 
Mice, Immunizations and Challenge Procedures. Female 
Balb/c mice (8-10 week old, Charles River Laboratories, 
10 Wilmington, Mass.) were immunized intranasally (i.n.) on 
days 0, 14 and 28 with IpaB (2.5 µg), IpaB complexed with 
IpgC (3.25 µg; equivalent to 0.75 µg IpgC and 2.5 µg IpaB) 
or IpaD (10 µg). The proteins were administered alone or 
15 combined, admixed with 2.5 µg of the E. coli dmLT adju-
vant. Control groups received 2.5 µg of dmLT or PBS. 
Immunization was performed under Isoflurane anesthesia 
(Abbott Laboratories, North Chicago, Ill.) dispensed 
through a precision vaporizer. The inoculum volume was 25 
20 µl and it was administered by means of a pipette and tip, 
delivering half of the volume in each nare. Animals were 
allowed to completely recover before they were returned to 
their cages, and they were monitored daily after immuniza-
tion. On day 56 after primary immunization, mice were 
25 challenged with virulent Shigella strains via the nasal route 
to induce a pulmonary infection, as previously described. 
Two lethal dosage levels were used for both S. jlexneri 
(6xl07 and 1.3xl08 CFU), corresponding to 11 and 24 
30 
35 
40 
MLD50, and S. sonnei (1.lxl08 and 2xl08 CFU), corre-
sponding to 5 and 9 MLD50, respectively. The challenge 
inoculum was given in a volume of 30 µl PBS. Mice were 
monitored daily for 14 days after the challenge, and their 
health status, daily weight and survival were recorded. Mice 
were euthanized if they reached the moribund state or lost 
more than 20% of their initial body weight and did not 
recover within 48 h. Animal studies and procedures were 
approved by the University of Maryland Institutional Ani-
mal Care and Use Committee. 
Measurement of Antibodies. Serum IgG antibodies to 
IpaB, IpaD and dmLT were measured by enzyme-linked 
immunosorbent assay (ELISA). Briefly, Immulon II ELISA 
plates (Thermo Scientific, Waltham, Mass.) were coated 
with IpaB (0.1 µg/ml), IpaD (1 µg/ml) or dmLT (1 µg/ml) 
diluted in PBS, for 3 h at 37° C. Plates were washed with 
45 PBS Tween (PBST) and blocked overnight with PBS con-
taining 10% dry milk (Nestle, Solon, Ohio). Serum samples 
were added in serial dilutions in PBST 10% dry milk and 
incubated for 1 h at 37° C. Antibodies were detected with 
Far-UV circular dichroism (CD) spectra were collected 
using a Jasco 1815 spectropolarimeter equipped with a 
Peltier temperature controller (Jasco Inc., Easton, Md.). 
Spectra were acquired using a 0.1 cm path length cuvette at 
10° C. A resolution of 1.0 nm and a scanning speed of 50 
mn/min with a 2-s data integration time were employed. 
Spectra presented are an average of three consecutive mea-
surements. The thermal unfolding of the proteins was fol- so 
lowed by monitoring the ellipticity at 222 nm over a 
temperature range of 10 to 90° C. with a resolution of 2.5° 
horseradish peroxidase (HRP)-labeled goat anti-mouse IgG 
followed by TMB substrate (KPL, Gaithersburg, Md.). The 
reaction was stopped by adding IM H3PO4. Plates were 
read using an Ascent microplate reader (Thermo Scientific, 
Waltham, Mass.). Titers were calculated by interpolation of 
Abs values of experimental samples in the regression curve 
of a calibrated positive control; they are reported in ELISA 
Units (EU) per ml and correspond to the inverse of the serum 
C. and 15° C./h heating rate. Protein concentration was 0.5 
mg/mL for IpaD and 0.3 mg/ml for IpaB and IpaB/IpgC. CD 
signals were converted to mean residue molar ellipticities 55 
[8h and the thermal transitions were analyzed using the 
Jasco Spectral Manager™ and Microcal Origin™ 6.0 soft-
ware. 
dilution that produces anAbs450 of0.2 above the blank. For 
measurement of stool antibodies, 5-6 fecal pellets from 
individual animals were weighted and resuspended 10% Challenge Organisms. S. jlexneri 2a 2457T and S. sonnei 
53G inocula for challenge were prepared as previously 
described. Briefly, the strains were grown on tryptic soy agar 
(TSA) with Congo Red (final concentration 0.02%); 20-25 
colonies were picked and grown in a volume of 125 ml 
Luria-Bertani (LB) broth (Athena Environmental Sciences, 
Baltimore, Md.) with agitation for 3-4 hours at 37° C. or 
until an Abs600 of 0.8-1.3 was achieved. Cultures were 
centrifuged and bacterial pellets were resuspended in phos-
60 W/V in PBS containing 0.2% sodium azide (Sigma-Aldrich, 
St Louis, Mo.). Samples were centrifuged and supematants 
stored at -20° C. with 1 mM phenylmethylsulfonyl fluoride 
(PMSF) (Sigma-Aldrich). IgA antibodies to IpaB, IpaD and 
dmLT were measured in stool supematants by ELISA, as 
65 described above, using HRP-labeled goat anti-mouse IgA as 
the secondary antibody (SouthernBiotech, Birmingham, 
Ala.). 
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Antibody Secreting Cells (ASC). The frequency of IgG-
and IgA-secreting cells was measured by ELISpot as pre-
viously described, with modifications. Spleen, bone marrow 
and nasal associated lymphoid tissue (NALT) were collected 
on day 39 and 56 after immunization and single cell sus- 5 
pensions were prepared. Cells were incubated overnight in 
Immulon II flat bottom plates (Thermo Scientific) previously 
coated with 5 µg/ml IpaB or IpaD; PBS-coated wells were 
used as negative controls. HRP-labeled goat anti-mouse IgG 
(KPL) and IgA (SouthemBiotech) were added in agarose 10 
overlay. True Blue (KPL) was used as substrate. For all 
ELISpot measurements, spots were counted using a stereo-
microscope and results were expressed as mean spot-form-
ing cells (SFC) per 106 cells from quadruplicate wells. 
IFN-y Secretion. The frequencies of IFN-y-secreting T 15 
cells were measured as previously described. Spleens were 
collected on day 56 following primary immunization and 
single cell suspensions were prepared. Cells (in quadrupli-
cate wells) were incubated with IpaB or IpaD (10 µg/ml) in 
plates previously coated with anti-IFN-y capture antibody 20 
(IFN-y ELISpot kit, BD Biosciences, San Diego, Calif.) for 
48 h at 37° C., 5% CO2 . IFN-y production was detected 
using a biotinylated anti-IFN-y antibody, followed by 
Streptavidin-HRP. 3-Amino-9-ethylcarbazole was used as a 
peroxidase substrate (Calbiochem, San Diego, Calif.). SFC 25 
were calculated and reported as described above. 
Statistical Methods. All graphics and statistical analysis 
were generated using GraphPad Prism 5. Data distribution 
was first examined using the D' Agostino & Pearson nor-
mality test. One-way ANOVA and Tukey's tests were used 30 
for subsequent group comparisons. Survival curves were 
plotted in Kaplan-Meier curves; treatments were compared 
using a log rank test. A P<0.05 was considered significant in 
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proteins, thermal unfolding curves were collected. As pre-
viously reported, IpaD exhibited an initial transition at 60° 
C. and a second transition at 80° C. in which the protein 
completely unfolds and precipitates (FIG. 2B). When the 
IpaB and IpaB/IpgC thermal unfolding curves were 
obtained, only one transition was seen regardless of the 
presence of the chaperone (FIG. 2B). Although preliminary 
results have indicated that IpaB forms a multimeric com-
plex, the IpgC still acts to stabilize IpaB, which is demon-
strated by the increase in the thermal unfolding from 60° C. 
for IpaB to 70° C. for IpaB/IpgC. 
To determine the initial stability of the proteins under 
standard storage conditions, IpaD, IpaB and IpaB/IpgC in 
PBS were stored at 4 ° C. or -80° C. and assessed for 
degradation weekly, for a three-month period, using SDS-
PAGE. IpaD remained stable for up to three months regard-
less of temperature ( data not shown). Both IpaB and IpaB/ 
IpgC were stable for three months at -80° C. In contrast, 
IpaB and IpaB/IpgC were stable for only three and four 
weeks at 4° C., respectively. In light of the thermal stability 
described above, it was surprising that the IpaB/IpgC com-
plex degraded 25% faster than IpaB alone at 4° C., albeit 
only one week. While these data appear contradictory to the 
thermal unfolding where the complex was more stable, it is 
likely that binding of IpgC to IpaB results in unstructured 
regions that are unique to the complex and are available to 
proteolytic cleavage. 
Mucosa! immunization with IpaB/D proteins elicits 
strong antibody responses. The kinetics of serum IgG 
responses against Shigella IpaB and IpaD and the E. coli 
dmLT adjuvant are shown in FIG. 3. Mice immunized i.n. 
with the Ipa proteins alone (i.e. IpaB, the IpaB/IpgC com-
plex, and IpaD) or combined (i.e. IpaB+IpaD or IpaB/IpgC+ 
IpaD), in the presence of dmLT, developed robust antigen-all analyses. 
Results 
Purification of Recombinant Shigella IpaB and IpaD. 
Purification of recombinant IpaD and IpaB was performed 
by modification to previous methods. In addition to the 
standard IMAC purification, contaminating proteins were 
removed from the His-tag IpaD via anion exchange chro-
matography (FIG. 1). The association of IpaB with its 
cognate chaperone, IpgC, is required for IpaB stability in the 
Shigella cytoplasm. Thus, we previously purified the over-
expressed IpaB/IpgC complex via a His-tag genetically 
fused to the N-terminus oflpgC. To more efficiently capture 
IpaB, the plasmid constructs were modified to fuse the 
His-tag to the N-terminus of IpaB, leaving the IpgC 
untagged. After standard IMAC purification, the complex 
was further purified via hydrophobic interaction chromatog-
raphy (FIG. 1). When His-tag IpaB alone was required, the 
His-tag IpaB/IpgC complex bound to the IMAC resin was 
incubated with 1 % OPOE. IpgC was washed away and the 
His-tag IpaB eluted with buffer containing OPOE. His-tag 
IpaB was further purified by size exclusion chromatography 
(FIG. 1). 
35 specific antibody responses. Serum IgG antibodies to IpaB 
were detected soon after immunization, i.e., 2 weeks after 
the first vaccine dose, whereas antibodies against IpaD 
appeared later, i.e., 2 weeks after the second immunization. 
For both IpaB and IpaD, serum IgG levels reached a plateau 
Far-UV CD was employed to assess the secondary struc-
ture of the purified proteins. These spectra are routinely 
collected to ensure the purification process has resulted in 
proteins maintaining their proper conformation. Thus, CD 
was used to demonstrate that the proteins were unaffected by 
the additional purification steps. Indeed, the spectra for 
IpaD, IpaB and the IpaB/IpgC complex exhibit the typical 
a-helical minima at 208 and 222 nm (FIG. 2A). While 
additional purification steps have been added to remove 
contaminants, these spectra illustrate that the contaminants 
have not contributed significantly to previous measure-
ments. To assess the stability of the purified recombinant 
40 after the third immunization. No differences were seen in the 
serum IgG responses to either of the vaccine antigens among 
the different groups regardless of whether the Ipa proteins, 
admixed with dmLT, were administered alone (IpaB, IpaB/ 
IpgC or IpaD) or combined (IpaB+IpaD and IpaB/IpgC+ 
45 IpaD). Interestingly, despite the fact that the amount oflpaB 
used for immunization was a fraction (1 :4) of the amount of 
IpaD (2.5 µg vs. 10 µg), the antibody responses to IpaB 
consistently surpassed the responses induced by IpaD in at 
least 1 log, at all time points examined (p<0.05), and in all 
50 the experiments performed. The amount of IpaB and IpaD 
used for immunization was established in preliminary dos-
ing experiments in which increasing quantities of either 
protein (2.5 µg to 20 µg) were administered with dmLT. 
Increasing amounts of dmLT were also tested. We selected 
55 the 1 :4 dose ratio (2.5 µg oflpaB and 10 µg oflpaD) and 2.5 
µg of dmLT for subsequent experiments because when 
combined in such proportion, the proteins were well toler-
ated and reached the highest responses within the variables 
tested. The IpaB/IpgC complex was not included in dose-
60 finding studies, but was used in the same amount as IpaB. 
Very strong serum IgG responses were also produced 
against the adjuvant E. coli dmLT. Elevated titers were 
detected 2 weeks after vaccination and reached a plateau 2 
weeks after the second dose. No differences were seen in 
65 titers among the different treatment groups. The dmLT-
specific IgG responses were consistently high in all the 
experiments performed. 
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!pa-specific IgA- and IgG-secreting cells in systemic 
tissues. In addition to serum antibodies, we measured the 
frequency of vaccine-induced ASC in spleen and bone 
marrow. These cells represent pools of long-lived plasma 
cells and memory cells, respectively, which have the capac- 5 
ity to maintain circulating antibody levels. IgG and IgAASC 
specific for IpaB and IpaD were detected in the spleen of 
vaccinated mice one month after the last immunization 
(FIG. 4A). Mice that received IpaB or the IpaB/IpgC com-
10 plex, either alone or co-administered with IpaD, developed 
18 
(FIG. 6). The frequencies of IpaB-specific ASC were again 
higher than those measured against IpaD (P<0.05). No 
significant differences were seen in the number of ASC 
against IpaB and IpaD among the different groups, regard-
less of whether IpaB or IpaB/IpgC were used, or whether 
these proteins were given alone or co-administered with 
IpaD. 
Intranasal immunization with IpaB and IpaD elicits robust 
T cell-mediated immunity. In addition to antibodies, T cells 
are also believed to contribute to protection against Shigella 
infection through the secretion of pro-inflammatory media-
tors that will further activate innate immune cells and T 
helper cytokines that will support antibody production. T 
cells might also contribute to clearing the infection by 
promoting T cytotoxic- or NK-mediated killing of infected 
cells. The frequency of IFN-y secreting T cells specific for 
IpaB and IpaD was measured in spleens of vaccinated and 
control mice, one month after the last immunization (FIG. 
high frequencies of IpaB-specific IgA- and IgG-secreting 
cells (between 200-300 SFC per 106 cells). ASC responses 
against IpaD were also detected, albeit frequencies were 
lower than those against IpaB (P<0.05). While responses to 15 
IpaB included both IgG- and IgA-secreting cells, the ASC 
responses to IpaD consisted primarily oflgG-secreting cells 
(10-150 SFC per 106 cells). Similar ASC response profiles 
and levels were seen in the spleen on day 39 after immu-
nization (data not shown). 
Similarly, vaccine-induced IgG- and IgA-secreting cells 
against IpaB were found in the bone marrow of vaccinated 
mice (FIG. 4B). ASC responses were also produced against 
IpaD, albeit at significantly lower levels (P<0.05). The 
frequencies of ASC responses against both IpaB and IpaD in 25 
the bone marrow were lower ( <30 SFC per 106 cells) than 
the frequencies measured in the spleen (40-300 per 106 
cells). In this tissue, we did not see the prevalence of 
IpaD-specific IgG ASC found in the spleen, possibly 
because all responses to IpaD were markedly low. When 30 
comparing ASC responses among the different groups and 
treatments, the ASC responses to IpaB and IpaD were 
similar regardless of whether IpaB was complexed or not 
with IpgC or whether IpaB and IpaD were given alone or 
35 
combined. No ASC responses to IpaB and IpaD were 
detected in mice that received dmLT alone or in the PBS 
controls. 
20 7). Intranasal immunization with IpaB and IpaD induced 
antigen-specific T cells that were able to produce IFN-y 
when stimulated in vitro. The IFN-y responses to IpaB 
(50-150 SFC per 106 cells) were higher than those measured 
Stool IgA and nasal ASC responses following immuniza-
tion with IpaB and IpaD. To demonstrate the induction of 40 
antibodies in the gastrointestinal mucosa, which represent 
the first line of adaptive immune defense against enteric 
pathogens, we measured IgA responses to IpaB and IpaD in 
stool supernatants from vaccinated and control mice (FIG. 
5). The kinetics oflpaB-specific IgA production were simi- 45 
lar among the different groups. Different from the serum IgG 
responses, which appeared relatively soon after vaccination, 
the fecal IgA were somewhat delayed. IgA titers to IpaB 
were first seen after the second immunization; IgA responses 
to IpaD appeared after the third, indicating that additional 50 
vaccine dose was required to raise detectable mucosa! 
antibodies, as compared with serum. Similar to the serologi-
cal responses, the intestinal IgA responses to IpaD were 
significantly lower compared to those against IpaB. For both 
55 
antigens, IgA titers reached a plateau 2 weeks after the third 
immunization. No differences were seen in the IpaB stool 
IgA titers among the groups that received IpaB and IpaB/ 
IpgC alone or combined with IpaD. A trend of higher IpaD 
IgA responses was seen in mice immunized with IpaD alone, 60 
although not reaching statistical significance. Very high 
levels of stool IgA were produced in response to the dmLT, 
which were similar in all treatment groups; responses were 
detected after the first immunization and had already 
reached maximum levels after the second dose of vaccine. 65 
IgG and IgA ASC specific for IpaB and IpaD were 
detected in the nasal tissue on day 56 after immunization 
against IpaD (<50 SFC per 106 cells). An interesting finding, 
which was not paralleled in the serological analysis, was a 
trend of higher magnitude ofIFN-y secreting T cells in mice 
immunized with IpaB or IpaB/IpgC along with IpaD 
(P<0.05). This was true for the responses against both 
antigens, IpaB and IpaD. The frequencies of IFN-y produc-
ing cells were consistently lower in groups that received 
IpaB, IpaB/IpgC or IpaD alone. No responses were detected 
in negative control groups that received dmLT and PBS. 
Protection against S. jlexneri and S. sonnei lethal pulmo-
nary challenge. To determine the protective efficacy oflpaB 
and IpaD, vaccinated and control mice were subjected to a 
lethal pulmonary infection with homologous S. jlexneri 2a or 
heterologous S. sonnei (FIG. 8). Two lethal dosage levels 
were used to perform a more stringent protection analysis: 
0.6 and 1.3xl08 CFU of S.jlexneri, corresponding to 11 and 
24 MLD50, respectively, and 1.1 and 2xl08 CFU of S. 
sonnei, corresponding to 5 and 9 MLD50, respectively. 
Protective efficacy of the Ipa proteins when using the lower 
challenge dose was between 90 and 100% against S. jlexneri 
(FIG. SA) and between 60 and 80% against S. sonnei. The 
highest level of protection was seen in mice immunized with 
IpaB or IpaB/IpgC. When the challenge dose was doubled, 
the homologous and heterologous protection achieved in the 
vaccinated groups was somewhat lower but still significant 
when compared with the unvaccinated controls (FIG. SB). 
Immunization with IpaB afforded 50% protection against S. 
jlexneri, whereas 30% protection was attained when IpaB 
was co-administered with IpaD (FIG. SB). Protection 
against the higher challenge dose of S. sonnei was 50% in 
mice immunized with IpaB and 45% in mice that received 
IpaB co-administered with IpaD. The addition of IpaD did 
not increase the survival rate in any of the challenges, 
regardless of the challenge dose. Nevertheless, a significant 
proportion of mice immunized with IpaD alone (70 to 90%) 
were protected when challenged with the lower lethal infec-
tious doses, although this level of protection decreased 
drastically (20-30%) when they were exposed to a higher 
number of organisms of either strain. A summary of the 
protective efficacy values and statistical significance when 
comparing vaccinated vs. controls groups are shown in 
Table 1. 
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TABLE 1 
Protective efficacy (% survival) against Shigella ssp. in a lethal 
pulmonary challenge model. 
IpaB + IpgC + 
Dose IpaB + IpaD + IapD + IpgC + IpaD + 
Organism (CFU) dmLT dmLT dmLT dmLT dmLT dmLT 
S. flexneri 1.2 X 108 50* 20 30* ND ND 0 
S. sonnei 2.0 X 108 55.5* 30* 50* ND ND 0 
S. flexneri 6.0 X 107 100* 88* 90* 100* 90* 0 
S. sonnei 1.1 X 108 80* 70* 80* 80* 60* 0 
ND = Not determined. 
*P < 0.05 vs. group receiving dmLT (Log-Rank Test). 
Discussion 
15 
20 
PBS 
0 
0 
0 
0 
IpaB was the most immunogenic of the two proteins, 
consistently and across measurements. Both serum IgG and 
stool IgA responses to IpaB appeared faster and achieved a 
higher magnitude than the responses induced by IpaD. This 
superior immunogenicity was also seen at the T cell 
response level. The co-administration of proteins had no 
effect on their individual serological responses, although it 
appeared to have an impact in the T cell responses as 
discussed below. The presence of high frequencies of 
Despite intense efforts, the development of an effective 
vaccine against Shigella remains a daunting task. One of the 
main challenges in achieving an effective prophylactic tool 
against this pathogen is the need to protect against multiple 20 
serotype strains. Antibodies to LPS have been associated 
with serotype-specific protection against Shigellosis, yet the 
existence of structurally and antigenically different LPS 
molecules limits the applicability of an LPS-containing 
vaccme. 
Our approach to develop a safe and effective vaccine to 
prevent this disease involves the use of conserved proteins 
that could provide broad protection against multiple sero-
types. Among potential cross-protective antigens, we 
focused our attention on the exposed proteins of the TTSA. 
These proteins are encoded as part of the mxi-spa operon 
located on the large virulence plasmid that is present in all 
Shigella ssp. Thus, in addition to being nearly identical 
among pathogenic Shigella strains, they mediate critical 
35 
steps of bacterial pathogenesis. IpaB and IpaD were selected 
because of their significant roles during TTSS-mediated 
events that lead to bacterial invasion of epithelial cells. IpaD 
localizes to the needle tip where it controls further assembly 
25 IpaB/D specific ASC in the spleen indicates the capacity of 
the vaccine to induce a large pool of functional plasma cells, 
which are the source of systemic antibodies. The demon-
stration of antigen-specific ASC in the bone marrow indi-
cates the existence of B memory cells, which can reactivate 
30 upon a subsequent antigen encounter to mount a rapid and 
strong ananmestic response and thus contribute to long-term 
of the TTSA, as well as TTSS effector secretion. IpaB is 40 
subsequently recruited to the tip of the needle where it 
interacts with host membranes to initiate formation of the 
translocon/pore complex. Immunological effector mecha-
nisms (i.e. antibodies) that could interfere with their function 
protection. 
The ability to generate mucosa! antigen-specific ASC and 
to produce intestinal slgA are also important features of our 
IpaB/D-based vaccine, as these immunological effectors 
would be necessary to prevent mucosa! enteric infection in 
humans. Although the mechanisms of protection against 
Shigella have not been elucidated, mucosa! immune 
defenses are sought, as they block pathogens in the intestinal 
lumen, preventing their attachment and infection of epithe-
lial cells. !pa-specific slgA antibodies are expected to neu-
tralize TTSS interactions at the mucosa! epithelial barrier 
thereby preventing bacterial invasion of host cells. IgG 
antibodies might also contribute to protection when infec-
in vivo could potentially prevent bacterial infection, making 
them very attractive vaccine target antigens. 
45 tion has occurred, facilitating opsonophagocytic killing by 
polymorphonuclear neutrophils and macrophages. 
In addition to antibodies, both IpaB and IpaD induced 
high frequencies of IFN-y-secreting T cells demonstrating 
the presence of robust cell-mediated immunity. Production 
We examined the immunogenicity of IpaB and IpaD 
(alone or combined) in a mouse intranasal immunization 
model, using the E. coli dmLT as adjuvant, and demon-
strated that both proteins were able to induce robust serum 
and mucosa! antibody levels and elevated frequencies of 
antibody-secreting cells in mucosa! and systemic tissues. 
They also induced strong antigen-specific cell-mediated 
immunity responses, evidenced by the presence of IFN-y 
secreting T cells. Most important, very high levels of pro-
tection (80 to 100%) were achieved against a homologous 
and a heterologous strain using a lethal pulmonary challenge 
model. The dmLT molecule is a derivative of the heat-labile 
50 ofIFN-y is required for protection of mice against Shigella 
pulmonary infection. Likewise, T cell-mediated immunity is 
thought to be necessary for protection of humans against 
Shigellosis. IFN-y activated macrophages abrogate bacterial 
growth whereas, in the absence ofIFN-y, Shigella replicates 
55 intracellularly and further disseminates, which suggests an 
IFN-y mediated mechanism for controlling infection. Pro-
duction of IFN-y in response to IpaB has been demonstrated 
using peripheral mononuclear cells (PBMC) from infected 
enterotoxin of E. coli with two attenuating mutations in the 
enzymatically active A-subunit (R192G/L211A); these 60 
mutations effectively reduce enterotoxicity without impact-
ing the adjuvant properties of the molecule. It was chosen as 
an adjuvant for our studies because it has been shown to 
enhance the production of vaccine-specific humoral and 
cell-mediated immune responses in both the systemic and 65 
mucosa! compartments when it is included as part of a 
vaccine formulation. 
individuals or from subjects that received live attenuated 
vaccine organisms. 
In our studies, the production of IFN-y appeared to be 
increased when IpaB/D were administered together, as 
opposed to the proteins given alone, suggesting a synergistic 
or more effective activation of antigen-presenting cells or 
Thl lymphocytes. Interestingly, the increased responses 
appeared to be limited to T cells, as they were not seen in the 
antibody or ASC measurements. This effect was not due to 
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cross reactivity or contamination, as cells from mice immu-
nized with IpaB did not respond against IpaD and vice versa. 
Although IpaB degrades when expressed in the E. coli 
cytoplasm, it can be stably co-expressed and purified with its 
cognate chaperone, IpgC. The complex can then be sepa- 5 
rated by the addition of the detergent OPOE, which results 
in stable, multimeric IpaB. While IpaB would be the obvious 
antigen, separation from IpgC requires an additional puri-
fication step and the use of a non-GRAS detergent, OPOE, 
which is currently the only detergent found to efficiently 10 
separate the complex. This lengthens the purification pro-
cess and increases production costs. Thus, the question 
emerged as to whether IpaB/IpgC is as equally immuno-
genic as IpaB and could serve as vaccine antigen. We found 15 
no significant differences between IpaB and IpaB/IpgC in 
any of the responses measured. This finding could facilitate 
the production of a vaccine with a more simple production 
process and reduced costs. 
Mice immunized with IpaB/D were protected against 20 
Shigella lethal infection in a pulmonary challenge. Heter-
ologous protection was also observed using Shigella sonnei. 
Protection in the lower dose challenge was significant for all 
combinations of Ipa proteins tested. In agreement with the 
lower immune responses, immunization with IpaD afforded 25 
lower protection compared with IpaB. Protection conferred 
by IpaB/IpgC was comparable to that induced by purified 
IpaB. 
Contrary to what we expected, the combination IpaB/D 
did not result in increased protection in any of the challenge 30 
conditions. We believe, however, that it would still be 
advantageous to maintain both antigens in a future vaccine 
candidate since IFN-y responses seemed to be improved, 
which might be important to enhance protection in humans. 35 
Another vaccine candidate that contains Shigella Ipas is 
the "Invasin-LPS complex" or Invaplex. This vaccine con-
sists of a mixture of IpaB, IpaC and LPS ( and possibly other 
antigens) present in water extracts from intact Shigella. Two 
chromatographic fractions, designated Invaplex 24 and 50, 40 
were immunogenic and protective against homologous viru-
lent strains in mice and guinea pigs. The S. jlexneri 2a 
Invaplex 50 vaccine was safe and immunogenic when 
administered intranasally to human volunteers in Phase 1 
clinical studies. However, this vaccine failed to protect 45 
subjects from a subsequent oral challenge with virulent S. 
jlexneri 2a 2457T. Unlike the Invaplex, our vaccine contains 
known quantities of highly purified IpaB, along with IpaD, 
and it does not contain LPS. 
Although antibodies to LPS are known to mediate pro- 50 
tection against shigellosis, our study provides the first evi-
dence that protective immunity can be induced by the 
IpaB/D vaccine combination, and in the absence of LPS. A 
protein-based, LPS-free vaccine would be safer and ame-
55 
nable for use in infants, young children and immune-
compromised individuals. The demonstration of cross-pro-
tective immunity using purified TTSA proteins is also novel 
and has broader implications as the TTSA tip proteins from 
other Gram-negative enteric pathogens could prove to be 60 
protective antigens as well. Through the use of efficient 
antigen delivery systems, TTSA-based vaccines could 
potentially be administered to humans to induce mucosa! 
immunity. 
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Example 2 
Generation of an IpaD-IpaB Chimeric (Fusion) 
Protein 
Two proteins sit at the tip of the Shigella TTSA needle. 
IpaD resides at the top of the TTSA needle; however, upon 
activation oflpaD, IpaB mobilizes to a position at the needle 
tip distal to IpaD and is responsible for host cell contact by 
Shigella. These two proteins are exposed to the immune 
system and are thus prime vaccine candidates. 
Example 1 describes purification of IpaD and IpaB via 
His-tag technology using pET plasmid vectors ( commer-
cially available from Novagen). While IpaD can be purified 
by standard methods, IpaB requires co-expression with its 
chaperone IpgC in a method similar to that published by 
Birket, et al. (Biochemistry [2007] 46:8128-8137). In order 
to release IpgC from IpaB, the detergent OPOE was added. 
OPOE is not a GRAS reagent and therefore must be 
removed from the purification scheme or replaced. There-
fore, in addition to IpaD and IpaB alone, the IpaB/IpgC 
complex was used to vaccinate mice intranasally, followed 
by Shigella challenge (FIGS. 9 and 10).The results showed 
that these proteins provided significant protection from the 
Shigella challenge, and the IpaB/IpgC complex was as 
protective as the IpaB alone. 
However, the use of a protein complex in a vaccine 
composition may not be optimal. Thus, a third method of 
preparation of the proteins in the form of a chimeric protein 
oflpaD-IpaB was undertaken. The genes for IpaD and IpaB 
were genetically fused and inserted into the vector pET15b. 
To produce the plasmid, an NdeI/XhoI PCR fragment of 
IpaD without a stop codon was subcloned 5' to an Xhol/ 
BamHI IpaB in pET15b. The plasmid was cotransformed 
into Tuner (DE3) with IpgC/pACYCDuet-1. This strain was 
used to inoculate LB media containing ampicillin and 
chloramphenicol. The bacteria were grown to an absorbance 
at 600 of about 0.6 at which time they were induced to over 
express the fusion/IpgC with Isopropyl-~-D-thio-galacto-
side (IPTG). The bacteria were grown an additional three 
hours to allow protein expression to occur. Alternatively, a 
starter culture of 100 ml was used to inoculate a 5- or 10-liter 
fermentor vessel containing TB media. After growing over-
night (16 hours), the bacteria were induced and allowed to 
express protein for three hours. The bacteria were collected 
by centrifugation, resuspended in binding buffer (see below 
for recipe), and lysed by microfluidization. This suspension 
was clarified by centrifugation and was loaded onto a nickel 
charged immobilized metal affinity column (IMAC). The 
column (5 ml) was washed with 10 bed volumes each of 
binding and wash buffers and then subjected to a gradient of 
0% to 40% elution buffer. Peak fractions were collected, the 
buffer exchanged into IM ammonium sulfate in 50 mM 
sodium phosphate pH 7 .0 and loaded onto a Butyl Sepharose 
High Performance colunm (5 ml) with a linear gradient from 
IM ammonium sulfate in 50 mM sodium phosphate pH 7.0 
to 50 mM sodium phosphate. For preparation of His-tag 
fusion, the !MAC-bound protein complex was incubated 
overnight in the presence of 1 % OPOE. The chaperone was 
removed in the flow through and subsequent wash steps. 
His-tag fusion was eluted in the presence of OPOE to 
maintain the protein in a soluble form. His-tag fusion was 
then further purified using size exclusion chromatography 
In sum, a subunit-based IpaB/D vaccine could be an 
effective broadly protective vaccine for prevention of shig-
ellosis. 
65 using a HiLoad 16/60 Superdex 200 Prep Grade colunm. All 
proteins were concentrated by ultrafiltration and dialyzed 
into PBS pH 7.2. Protein concentrations were determined 
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via absorbance at 280 run using extinction coefficients based 
on the amino acid composition of each protein. 
This method produces a chimeric IpaD-IpaB protein that 
is stable and soluble. An SDS-PAGE picture of the purified 
protein is shown in FIG. 11. Further, when the plasmid is 5 
cotransformed with a plasmid encoding ipgC (in pACYC-
Duetl ), a multimeric protein complex oflpaD-IpaB/IpgC is 
formed that is similar to the one that forms from IpaB and 
IpgC by themselves. Importantly, this method allows a 
cGMP facility to produce both proteins with a single (i.e. 10 
one) fermentor run, thereby reducing the protein purification 
costs. Those of skill in the art will recognize that this is a 
very important factor when producing vaccines for <level-
24 
generation of memory B cells was demonstrated in the bone 
marrow, suggesting long lasting immunity. 
FIG. 15A-C shows the results of an analysis of IFN-y 
secreting cells, cytokine secretion, and IL-17 secretion, 
respectively. Spleen cells were extracted and stimulated with 
IpaB or IpaD; supernatants were collected and analyzed for 
cytokine secretion. In addition, the frequency of IFN-y 
secreting cells was also determined. 
As can be seen, the DB fusion was able to generate a 
higher specific cytokine response in the case of IFN-y 
secreting cells and secretion levels of IL-17 and IL-2, 
compared to the administration of IpaB and IpaD. This 
demonstrates that the DB fusion protein has a unique 
oping countries. 15 advantage in the generation of cell-mediated immunity, 
Example 3 
which can be important for control of Shigella infection. 
The detergent effects on the secondary structure of the 
IpaD/B fusion protein were assessed using circular dichro-
ism (CD). The experiments were carried out using 0.3 mg.ml 
Further Characterization of Chimeric IpaD-IpaB 
Fusion Protein 
20 of protein in the presence of the detergents octyl polyoxy-
ethylene (OPOE) and lauryldimethylamine-oxide (LDAO), 
compared to a combination oflpaD and IpaB proteins in the 
presence of OPOE, and IpaD/B fusion in phosphate buffered 
saline (PBS) after dialysis to remove LDAO detergent. The 
Additional testing and characterization of the IpaD-IpaB 
fusion protein (also referred to as "DB" or "DB fusion") has 
also been carried out. In one experiment, mice were divided 
into 4 groups, A, B, C and D, and immunized as follows: 
Group A: 12 µg IpaB+ 7 µg IpaD+2.5 µg dmLT; Group B: 20 
µg DB fusion+2.5 µg dmLT; Group C: 20 µg DB fusion; and 
Group D: PBS (control). Intranasal immunization was per-
formed at days 0, 14 and 28. Serum IgG levels were 
monitored at days 0, 14, 28, 42 and 56. At Day 56, selected 
mice were euthanized and ASC and IFNy secretion were 
analyzed, and other mice were challenged with either S. 
jlexneri or S. sonnei. 
25 results are presented in FIG. 16. As can be seen, the spectra 
indicate that DB is an ordered highly a-helical protein 
displaying characteristic double minima at 208 and 22 run. 
The data also suggest that the DB protein is stable in the 
detergent LDAO. This could be advantageous when isolat-
30 ing the protein and/or when formulating vaccines composi-
tions; LDAO is much less expensive that OPOE and has a 
well-defined composition, in contrast to OPOE which is a 
heterogonous mixture. Further, the results showed that 
LDAO can be dialyzed out of a solution of DB in PBS and 
35 yet the protein remains soluble and maintains its secondary 
Serum IgG levels in the mice at days 0, 14, 28, 42 and 56 
are presented in FI GS. 13 A and B. Serum was obtained from 
immunized animals and antibody titers against IpaB and 40 
IpaD were determined by ELISA. As can be seen, the 
antibody titers against IpaB and IpaD elicited by the DB 
fusion are comparable to those generated by vaccination 
with the separate proteins IpaB and IpaD. The peak antibody 
levels and the kinetics follow a very similar pattern. Even if 45 
the DB fusion protein administered without dmLT is able to 
generate an antibody response the presence of the adjuvant 
dmLT is necessary for generating a strong antibody 
response. This result indicates that humoral responses are 
generated with similar levels as the vaccine which contains 50 
the IpaB and IpaD proteins mixed together. 
FIG. 14A-E show the results of ASC analysis at day 56 for 
lungs (14A), Peyer's patches (PP) (14B), nasal associated 
lymphoid tissue (NALT (14C), spleen (14D), and bone 
marrow (BM, 14E). At day 56, organs were extracted and 55 
single-cell suspensions were obtained. The frequency oflgG 
and IgA secreting cells specific for each antigen was deter-
mined by ELISpot. As can be seen, in agreement with the 
serum IgG titers described above, the frequency of antibody 60 
secreting cells shows no significant difference when the DB 
fusion is compared to the administration of the individual 
proteins. This result demonstrates that the observed humoral 
response elicited by the DB fusion occurs in similar com-
partments, with comparable (or in some instances higher) 65 
intensities for both antigens. Both treatments are able to 
induce an IgA response in several organs. Additionally, 
structure. 
The effects of temperature on the secondary structure of 
DB protein in the presence and absence ofOPOE and LDAO 
were also investigated by monitoring thermal melting using 
CD. The results are presented in FIG. 17. As can be seen, the 
DB protein in LDAO does not completely unfold at 90° C. 
Thus, in LDAO the DB protein is protected from heat 
indicated that it would be stable as a liquid form in the 
absence of a cold chain. 
The thermal stability of DB protein was also investigated 
using CD. CD spectra of IpaD plus IpaB proteins (1: 1 in 
0.5% OPOE, DB in 0.5% OPOE, DB in 0.05% LDAO and 
DB in PBS were acquired at 10° C., and the solution was 
then heated to 90° C. at a rate of 15° C./hour. Spectra were 
reacquired after the temperature was returned to 10° C. The 
results are shown in FIG. 18A-D. Under most conditions 
tested, the proteins precipitated and visible aggregation was 
observed. However, DB in 0.05% LDAO remained soluble 
and appeared to regain its native secondary structural char-
acteristics upon cooling back to 10° C. This is significant 
because upon heating and cooling the DB protein remains 
stable. Thus, in the absence of a cold chain or in that case of 
a disruption in the cold chain, the DB protein vaccine is not 
affected. 
DB fusion was also characterized with respect to its 
ability to mimic IpaB's ability to disrupt phospholipid 
membranes. IpaB is well characterized and is known to form 
tetramers in OPOE that efficiently disrupt liposomes through 
pore formation. A sulforhodamine B (SRB) dye release 
assay was used to assess the ability of DB to do so. In the 
assay, membrane disruption releases fluorescent dye from 
lipid vesicles, giving rise to an increase in fluorescence. The 
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results showed that IpaB in OPOE, IpaD+IpaB in OPOE and 
the DB fusion protein in OPOE all has similar membrane 
disruption efficiencies. Therefore, the DB fusion likely 
maintains at least some of the native structural characteristic 
oflpaB. (Notably, in LDAO detergent and in PBS buffer, DB 5 
and IpaB are both unable to cause membrane disruption.) 
Next, the quaternary oligomeric structure of DB was 
investigated. Chemical crosslinking studies with and with-
out the reducing agent dithiothreitol (DTT) and analyzed by 
gel electrophoresis identified the formation of extremely 10 
large DB fusion protein complexes. Both 0.5% OPOE and 
0.05% LDAO supported the monomeric form of the protein 
to some extent (OPOE more so than LDAO), although most 
of the protein did not migrate into the gel even in the 
presence of detergent. Once dialyzed into detergent free 15 
PBS, the protein exclusively formed large complexes (much 
larger than 500 kDa) which were unable to migrate into the 
gel. Dynamic light scattering was used to determine the 
physical size of the DP oligomers. Consistent with cross-
linking results, two predominant populations were identi- 20 
fled: an -5 nm diameter population (which may represent 
the monomer) and an -25 nm population (which may 
represent the oligomer). In the presence of OPOE, the 
smaller species was primarily present while the presence of 
LDAO allowed the formation of the larger oligomer (which 25 
was also observed in detergent free PBS. These results 
showed that the DB protein is stable in LDAO for long term, 
but when diluted into PBS in preparation for immunization 
forms a large multimer that would be similar to the principle 
associated with virus-like particles (VLP). Thus, the multi- 30 
mer has a greater probability for success in humans. 
Additional biophysical characterization if DB and subse-
quent analysis via an empirical phase diagram (EPD) has 
demonstrated that, in general, the fusion maintains its struc-
ture at pH 8 until higher temperatures are reached (not 35 
shown). At 60° C., the fusion protein in pH 6-7 buffer enters 
a molten globule state. The fusion in lower pH buffers does 
not exhibit exceptional stability at any temperature with high 
light scattering and noisy CD thermal melting curves (not 
shown). Interestingly, the fusion appears to exhibit mixed 40 
stability characteristics. At pH 8 the fusion appears to be 
more stable than IpaB with a transition temperature closer to 
70° C. At pH 6, the fusion is less stable than either IpaB or 
IpaD associated with IpaB with an increase in stability 
which is more like IpaD. EPD provides a measure of the 45 
effects of physical conditions on protein stability. This in 
turn allows development of improved formulation taking 
into account conditions that are best suited to a stable 
vaccine and those conditions not conducive to vaccine 
stability. In the latter case, it also provides the basis for the 50 
screening of stabilizing agents from a library of GRAS 
reagents. 
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resulting proteins can be used in humans The ipaD/pET9a-
Tuner (DE3) strain was used to over-express IpaD using the 
typical shake flask method as well as in the 10 L fermentor. 
Both methods produced over 10 milligrams of IpaD per liter 
as was seen for the initial pETl 5b plasmid, showing that this 
strain and the resulting protein are ready for vaccine devel-
opment. 
The ipaB/pET28b plasmid was also used to co-transform 
Tuner (DE3) with ipgC/pACYC-Duetl. It should be noted 
that protein expression of this strain is sensitive to bacterial 
growth media when grown in shake flasks and can be 
problematic. Maximal protein expression typically occurs in 
Terrific Broth (TB) media with overnight expression at 18° 
C. Nevertheless, milligram quantities of protein were puri-
fied from the co-transformed Tuner (DE3) cells. When 
protein expression was performed in a 10 L fermentor, 
excellent expression was also observed. The IpaB/IpgC 
complex was further purified by passage over a hydrophobic 
interaction chromatography (HIC) colunm and IpaB alone 
(i.e. without IpgC) was purified by immobilized metal ion 
affinity chromatography (IMAC) in the presence of OPOE. 
Triton X-100 has also been shown to release IpgC from 
IpaB. 
Example 5 
Protective Efficacy Using Homologous and 
Heterologous Shigella Spp. in the Guinea Pig 
Model 
A small pilot study was performed to confirm the lack of 
toxicity of the Ipa proteins following intranasal administra-
tion with target doses in guinea pigs. Two animals each were 
inoculated intranasally with 1) IpaB (25 µg)+IpaD (100 µg) 
or 2) IpaB (25 µg)+IpaD (100 µg)+dmLT (10 µg). Animals 
were observed for 5 days and all animals tolerated the 
vaccination well with no abnormal clinical signs. The doses 
were thus determined to be safe for use in the immunoge-
nicity/protection study. 
Intranasal (IN) Immunization of Guinea Pigs 
An experiment was conducted to assess intranasal (IN) 
immunization of guinea pigs using IpaB, IpaD, IpaB/IpgC 
and dmLT. The doses of protein given to the guinea pigs 
were: 25 µg of IpaB, 100 µg oflpaD, 32 µg IpaB/IpgC and 
10 µg of dmLT. The volume of inoculation was 30-50 µl (see 
Table 2). Immunization was performed on days 0, 14 and 28. 
Sera, tears (for measurement of secretory IgA) and fecal 
samples were collected to examine immune responses. 
Example 4 55 Three weeks after the last immunization ( day 49) the guinea 
pigs were challenged intraocularly with S. jlexneri 2a 2457T 
(1-5xl08 CFU). 
Further Characterization of IpaD and IpaB 
Expression 
In the studies described in Example 1, IpaD and IpaB 
were produced from plasmids that were maintained in E. coli 
by ampicillin resistance. Since ampicillin cannot be used in 
proteins produced for use in humans, the ipaB and ipaD 
genes were moved into pET28b and pET9a, respectively. 
Both plasmids are kanamycin resistant and therefore the 
The challenge results are shown in Table 3. As can be 
seen, 100% of animals immunized with the positive control 
60 strain CVD 1208S were protected against challenge. There 
were 75% and 100% attack rates in the negative control 
groups E and F immunized with PBS or dmLT respectively. 
Immunization with IpaB+IpaD+dmLT provided the highest 
level of protection (73%). Immunization with IpaB/IpgC+ 
65 dmLT provided 20% protection. Immunization with IpaB+ 
dmLT or IpaB/IpgC+IpaD+dmLT provided no protection 
against challenge. 
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TABLE 2 
Outline for Intranasal Immunization Experiment 
Group 
Day 1-2 
Dose #1 
Day 14-16 
Dose #2 
Day 28-30 
Dose #3 
Day 55-59 
Challenge 
A(n- 5) 
B (n - 5) 
C(n - 5) 
D (n - 5) 
E (n - 5) 
F (n - 5) 
G (n - 5) 
IpaB + dmLT IpaB + dmLT IpaB + dmLT S. flexneri 2a 
S. flexneri 2a 
S. flexneri 2a 
S. flexneri 2a 
S. flexneri 2a 
S. flexneri 2a 
S. flexneri 2a 
IpaB + IpaD + dmLT 
IpaB/IpgC + dmLT 
IpaB/IpgC + IpaD + dmLT 
PBS 
IpaB + IpaD + dmLT 
IpaB/IpgC + dmLT 
IpaB/IpgC + IpaD + dmLT 
PBS 
IpaB + IpaD + dmLT 
IpaB/IpgC + dmLT 
IpaB/IpgC + IpaD + dmLT 
PBS 
dmLT dmLT dmLT 
CVD 1208S (109 CFU) CVD 1208S (109 CFU) CVD 1208S(109 CFU) 
TABLE 3 
Protection against challenge following i.n. immunization. 
#animals reaching PE PE against 
an eye score of "4"/ Attack against combined 
Vaccination Group total #animals Rate PBS controls 
A(n- 5) 5/5 100% -33% -12% 
IpaB + dmLT 
B (n - 5) 1/5 20% 73% 78% 
IpaB + IpaD + 
dmLT 
C (n - 5) 3/5 60% 20% 33% 
IpaB/IpgC + dmLT 
D (n - 5) 4/5 80% -7% 10% 
IpaB/IpgC + IpaD + 
dmLT 
E (n - 4) 3/4 75% 
PBS 
F (n - 5) 5/5 100% -33% 
dmLT 
G (n -4) 0/4 0% 100% 100% 
CVD 1208S 
15 
20 
25 
30 
35 
Conclusions from intranasal immunization. Serum and 
mucosa! responses to the IpaB and dmLT antigens were 
similar in Groups A, B, C, and D. Responses to IpaD were 
similar in Groups B and D. The only striking difference in 
immune responses in Group B, the highly protected group, 
was an earlier strong response in all animals to IpaB 
following 2 doses instead of following 3 doses. 
Example 6 
Immunogenicity of IpaB/D-dmLT Administered 
Intradermally 
Immunogenicity and protective efficacy oflpaB and IpaD 
when administered orally using the mouse pulmonary model 
are remarkably lower compared with the responses induced 
when these proteins are given intranasally. Thus, an intrad-
ermal delivery approach was assessed. 
Immunology data was compiled to assess serum IgG and 
mucosa! (tears and fecal) IgAresponses to each antigen. All 
animals that were immunized with IpaB (Groups A, B, C, D) 
responded with strong serum IgG anti-IpaB responses fol-
lowing 3 doses (FIG. 19). Interestingly, Group B, immu- 40 
nized with IpaB+IpaD+dmLT responded earlier after only 2 
doses. Strong mucosa! IgA anti-IpaB responses were also 
measured in tears from the same groups (FIG. 19). Animals 
In order to define the adequate amounts of IpaB, IpaD and 
dmLT to deliver through intradermal injection, we per-
formed a dose finding experiment (FIG. 23) in which three 
dosage levels of protein were tested: 
1) low dose (50 ng IpaB/IpgC+l00 ng IpaD), 
2) medium dose (100 ng IpaB/IpgC+250 ng IpaD) and 
3) high dose (200 ng IpaB/IpgC+500 ng IpaD) 
The proteins were administered in the presence of 100 ng 
of E. coli dmLT. The volume of inoculum was 25 µI and it 
was dispensed using the NanoPass MicronJet 600 
microneedle device attached to a Hamilton syringe. Mice 
immunized with intranasally with 2.5 µg of IpaB/IpgC and in Group G, immunized with CVD 1208S responded with 
strong anti-IpaB IgG and IgA titers. This is consistent with 
volunteer studies in which humans orally immunized with 
CVD 1208S respond with anti-IpaB antibody responses. 
Animals in Groups E (PBS) and F ( dmLT) served as controls 
and did not have IpaB antibodies. 
Serum and mucosa! responses to IpaD were robust in 
Groups B and D which received the IpaD antigen (FIG. 20). 
No response to IpaD was measured following immunization 
with the vaccine strain CVD 1208S. 
45 10 µg of IpaD along with 2.5 µg of dmLT were included as 
positive control. Negative control groups received dmLT 
(100 ng) and PBS via the i.d. route. A total of 3 doses were 
administered on days 0, 14 and 28. Serum and stool samples 
were collected before the first immunization and every two 
50 weeks until day 56. On day 56, mice were subjected to lethal 
pulmonary challenge with Shigella jlexneri 2a. Five addi-
tional animals were euthanized at this time to measure 
systemic ASC and cell-mediated immunity. 
Serum and mucosa! responses to dmLT were very strong 
following a single dose in all groups that received the 55 
antigen (Groups A, B, C, D, F) and were boosted to higher 
levels following each subsequent immunization (FIG. 21). 
Anti-dmLT responses were not expected in animals immu-
nized with CVD 1208S (Group G). The responses measured 
Serum Antibody Responses 
FIG. 24A-C display the kinetics of A, IpaB-, B, IpaD-, 
and C, dmLT-specific serum IgG and stool IgA titers from all 
vaccinated groups and control groups. All groups of mice 
vaccinated intradermally responded with high levels oflpaB 
and IpaD-specific serum IgG titers. The titers to IpaB 
in pooled tears from Group D in BL-3 and BL-4 will be 
assessed by titering tears from individual animals in these 
groups. 
As expected serum and mucosa! responses to S. jlexneri 
2a LPS were measured only in Group G, immunized with 
CVD 1208S (FIG. 22). Mucosa! responses to LPS following 
intranasal inoculation with live attenuated strains are con-
sistently strong responses. 
60 increased significantly after the first and second immuniza-
tion and reached similar peak/plateau levels regardless of the 
amount of protein given. Overall, the serum IpaB-specific 
IgG titers induced by intradermal immunization were only 
slightly lower than those induced by the intranasal immu-
65 nization (positive control group). Robust responses to IpaD 
were also induced after intradermal vaccination. For these 
antibodies, however, there was a more noticeable difference 
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TNF-a and IL-1 produced in culture supematants of anti-
gen-stimulated cells are shown in FIG. 28A-F. High levels 
IFN-y, TNF-a and IL-2 were produced in response to IpaB 
in the magnitude of responses with regards to the dose. Mice 
immunized i.d. with the largest amounts of IpaD had 
elevated responses earlier (day 21), although titers in all 
groups reached comparable plateau levels after the 3rd 
immunization, at the time of challenge. The ID vaccinated 5 
animals also developed very strong serum IgG responses to 
the adjuvant dmLT. The dmLT-specific IgG titers were high 
(-1 xl 06 EU/ml) and consistent among all i.d. vaccinated 
groups, indicating that the inoculation and measurements 
were reproducible. 
Fecal Antibody Responses 
IpaB- and IpaD- specific stool IgA titers were found in the 
positive control group immunized with IpaB and IpaD i.n. 
but not in the animals immunized i.d., regardless of the 
amount of antigen given. Very high stool IgA responses 15 
against dmLT were observed in the positive control group, 
while very little (although detectable) IgA responses were 
found in mice immunized i.d. 
in all groups immunized i.d. and these responses were 
independent of the dose of antigen administered. Interest-
ingly, the levels ofTNF-a and IL-2 in response to IpaB were 
comparable for the i.n. and i.d. vaccinated mice. Modest 
production of TNF-a and IL-2 was observed in response to 
IpaD in the groups immunized intradermally. These 
10 
responses were also independent of the immunizing dose, 
and much lower than the responses observed in the positive 
control group immunized i.n. 
Mucosa!ASC 
No differences were seen in the production ofIL-12, most 
likely because this cytokine is non-specific and mainly 
produced by macrophages and antigen presenting cells, 
rather than antigen-specific T cells. Animals immunized i.d. 
produced IL-1 ~ in response to IpaB in levels comparable to 
those of the positive control group immunized i.n. (FIG. 
In order to assess the induction of mucosa! immunity in 
the lungs following intradermal immunization with the Ipas, 
20 29A-D). IL-1~ responses to IpaD were also detected in the 
i.d. immunized mice but at levels much lower than those 
we measured the frequency oflpaB, IpaD and dmLT-specific 
IgG and IgAASC in lymphocytes from the lungs on day 56 
after immunization; this time corresponds to the time of 
challenge (FIG. 25A-C). As observed in previous experi- 25 
ments, the positive control group immunized with IpaB and 
IpaD i.n. exhibited a large number oflpaB and IpaD-specific 
ASCs in the lung, whereas almost no responses were seen in 
the groups immunized i.d. regardless of the dose adminis-
tered. The ASC responses to IpaB surpassed those against 30 
IpaD, as seen in previous experiments. 
Very strong ASC responses against dmLT were observed 
in the control group. 
Systemic ASCs 
The frequency of IpaB and IpaD-specific ASC was mea- 35 
sured in the spleen and bone marrow of i.d. vaccinated mice 
on day 56 after immunization (FIG. 26A-C). The groups 
immunized intradermally had positive IpaB and IpaD IgG 
spleenASC responses that were clearly dose-dependent ( e.g. 
increased with the amount of protein administered). Both 40 
IgG and IgA ASC responses against IpaB and IpaD were 
also seen in the positive control; the IgA ASC responses in 
this group were comparable to those of mice immunized i.d. 
with the highest dose. 
IgA ASC responses specific for dmLT were also induced 45 
following i.d. vaccination, although at lower levels. It is 
interesting to notice that while i.n. immunization led to the 
production of both IgG and IgA ASC in the spleen, intrad-
ermal vaccination led to the production of IgG ASC only, 
and this was true for all 3 antigens. Only the group immu- 50 
nized i.n. had detectable levels of IgA ASC in the spleen. 
A similar pattern of responses was found in the bone 
marrow (FIG. 27A-C), except that in this case, similar 
frequencies of IgG ASC responses to IpaB and IpaD were 
measured in all groups, regardless of the dose of protein 55 
administered (for the i.d. groups) and the route of the 
immunization (animals immunized i.d. had similar levels to 
those immunized i.n. The IgA ASC responses to IpaB 
surpassed in magnitude the IgA ASC responses to IpaD. 
Again, i.n. immunization elicited both IgG and IgA ASC 60 
whereas i.d. immunization induced only IgG ASC. 
Cell-Mediated Immunity 
We measured the production of cytokines by spleens cells 
obtained on day 56 after immunization. To assess antigen-
specific cytokine production, cells were stimulated with 65 
IpaB or IpaD for 48 hours. The supernatants were tested 
using a TH1/TH2 multiplex system. The levels IFN-y, 
produced by the positive control group. Mice immunized i.d. 
produced IL-10, IL-4 and IL-5 in response to IpaB and IpaD 
(FIG. 30A-F). Interestingly, intradermal immunization led to 
higher levels of IpaB-induced IL-4 and IL-5 compared with 
intranasal immunization. This was also true for IpaD-in-
duced IL-5. 
When these animals were challenged with virulent organ-
isms using the pulmonary challenge model, up to 70% 
protection was observed in mice immunized with the 
medium dosage level, as described in detail below. Surpris-
ingly, no protection was seen in mice receiving the highest 
dose of IpaB and IpaD. These observations prompted us to 
perform a second experiment where we included groups 
receiving both the medium and the high doses of antigen 
used in the previous experiment. To confirm the immune 
enhancement effect of the dmLT, the proteins were given in 
the presence and absence of dmLT (FIG. 31). The IpaB 
protein used did not contain the IpgC chaperone. A total of 
25 mice were included in each group to accommodate 
pulmonary challenge with both S. jlexneri and S. sonnei and 
collection of tissue for immunological assays on day 35. 
The kinetics of serum IgG specific for IpaB, IpaD and 
dmLT from the previous experiment is shown in FIG. 
32A-C. Mice that received both the high and medium doses 
of IpaB and IpaD in the presence of dmLT had the highest 
responses to IpaB and these responses were similar to those 
observed in the positive control group immunized i.n. with 
IpaB, IpaD and dmLT. In the absence of dmLT, titers against 
IpaB were noticeably lower. Serum IgG responses against 
IpaD were also produced in all groups immunized i.d. and 
titers of higher magnitude were also observed in the pres-
ence of dmLT. 
Mucosa! ASC 
To assess the induction of mucosa! immunity, we mea-
sured the frequency oflgG and IgAASC in the NALT, lungs 
and PP (FIGS. 33A-C, 34A-C and 35A-C). Different from 
the previous experiment, these measurements were per-
formed on day 35 after immunization. In contrast to our 
previous findings from day 56, we were able to detect IpaB-, 
IpaD- and dmLT-specific ASC in the lungs of i.d. vaccinated 
mice, on day 35. IgAASC responses to both IpaB and IpaD 
were noticeable in the group receiving the medium antigen 
dose in the presence of dmLT. This group also developed 
IgG and IgA ASC responses to dmLT IgG ASCs responses 
to both IpaB and IpaD were detected in the NALT of i.d. 
immunized mice. 
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For the most part, these responses were lower than those 
of mice immunized i.n. and did not follow a defined pattern. 
Detectable IgA and IgG ASC responses to both IpaB were 
observed in the Peyer's patches of i.d. immunized mice at 
levels comparable with those induced in the intranasal 5 
positive control. IpaD-specific IgG and IgA responses were 
seen in the i.d. vaccinated mice. 
Systemic ASCs 
IpaB and IpaD-specific IgG and IgAASC responses were 
measured in the spleen and bone marrow tissue collected on 10 
day 35 (FIG. 36A-C). As observed for the ASC measured on 
day 56, IgG ASC responses to IpaB and IpaD were induced 
by i.d. immunization and these responses were similar to 
those of the positive control group. A difference with the 
control group was that the latter also developed high levels 15 
oflpaB and IpaD-specific IgAASC that were much lower or 
absent in the i.d. vaccinated mice. 
Antibodies in BAL 
32 
70% protection; while the high and low doses ID groups 
resulted in 0% and 30% survival, respectively. 
Survival Against Lethal Pulmonary S. Flexneri Challenge 
High and medium doses of IpaB and IpaD, along with 
dmLT were included; 10 mice from each group were chal-
lenged with S. jlexneri on day 56 after the initial immuni-
zation. The challenge doses used was 5.4xl07 CFU in a 30 
µl volume. The group receiving the medium dose+dmLT 
again showed 70% survival (FIGS. 39A and B). In the 
absence of dmLT the protection of the medium dose group 
dropped to 50%. The group immunized with the highest 
dose of IpA antigens alone had 40% survival and the 
presence of the dmLT in this group did not improve survival 
(30% survival). 
Survival Against Lethal Pulmonary S. Sonnei Challenge 
Another subgroup of 10 mice from each immunization 
group was challenged with S. sonnei. The challenge dose 
used was 1.35xl 08 CFU of S. sonnei in a 30 µl volume. The 
highest survival, 50%, was seen in the group immunized In agreement with the presence of IgG ASC in the lung 
tissue, we also detected IgG antibodies specific for IpaB and 
IpaD in bronchoalveolar lavages from mice immunized i.d. 
(FIG. 37 A-C). The level of antibodies did not increase with 
the dose. Interestingly, we did not detect production of IgA 
antibodies against the Ipas in these lung lavages, despite the 
presence of ASCs in the lung tissue of these mice. Both IgA 
and IgG antibodies against dmLT were present in the bron-
choalveolar lavages of i.d. vaccinated mice. 
20 with the medium dose of proteins in the presence of dmLT 
(FIGS. 39A and B). The percent survival dropped to 20% 
when dmLT was absent. The high dose group+dmLT had 
only 10% survival. The presence of dmLT along with the 
high dose of IpA proteins did not improve survival; it 
25 actually reduced it in both experiments for reasons unknown 
(40% survival in the absence of dmLT). In both challenges, 
100% protection was seen in the positive control group. 
Conclusions: The results demonstrate that intradermal 
immunization of mice with IpaB and IpaD in the presence of 
dmLT, using the NanoPass MicronJet 600 microneedles, 30 
induce a very strong serum IgG and systemic IgG ASC 
response as well as Thi and Th2 cytokine production. 
Example 7 
The Determination of Protective Efficacy for the 
Intradermally Administered IpaB/IpaD-dmLT 
Against S. Flexneri 2a and S. Sonnei V sing the 
Mouse Pulmonary Lethal Challenge Model 
35 
Example 8 
Protective Efficacy Using Homologous and 
Heterologous Shigella Spp. in the Guinea Pig 
Model 
Microneedle and adapter devices were tested for use in 
the guinea pig. The adapter method was chosen since this 
device was readily available and i.d. injection was efficient 
using the adapter. The intradermal experiment was com-
pleted in which guinea pigs (Hartley strain), 10 per group, 
Survival Against Lethal Pulmonary S. Flexneri Challenge 
40 were immunized i.d. with the IpaB/D vaccine candidates and 
dmLT as described in Table 4. The doses chosen were based 
Mice were immunized with increasing doses oflpaB and 
IpaD along with dmLT on days 0, 14 and 28 as described for 
FIG. 23. On day 56 after the initial vaccination, mice were 
subjected to lethal pulmonary challenge with Shigella flex- 45 
neri 2a. The challenge dose used was: 5.8xl07 CFU of S. 
jlexneri 2a in a 30 µl volume. FIG. 38 shows the survival 
curves for all immunized animals. Full (100%) protection 
Day 1 
Group Dose #1 
on results from mouse studies wherein optimal efficacy was 
achieved using the middle dose tested. The middle mouse 
doses were adjusted for body weight of guinea pigs. For 
intradermal inoculation 1.0 µg IpaB, 2.5 µg IpaD and 1.0 µg 
dmLT were used. For the repeated intranasal immunization 
(Group D) inoculation with 25 µg IpaB, 100 µg IpaD and 10 
µg dmLT were used. 
TABLE 4 
Outline for Intradermal Immunization Experiment. 
Day 28 Day 56 Day 84 
Dose #2 Dose #3 Challenge 
A(n- 10) IpaB + IpaD (ID) IpaB + IpaD (ID) IpaB + IpaD (ID) S. flex 2a 
Al-AlO 
B (n - 10) IpaB + IpaD + dmLT IpaB + IpaD + dmLT IpaB + IpaD + dmLT S. flex 2a 
Bll-B20 (ID) (ID) (ID) 
C(n - 10) PBS PBS PBS S. flex 2a 
C21-C30 
D (n - 10) IpaB + IpaD + dmLT IpaB + IpaD + dmLT IpaB + IpaD + dmLT S. flex 2a 
D31-D40 (IN) (IN) (IN) 
E(n - 5) CVD 1208S CVD 1208S CVD 1208S S. flex 2a 
E41-E45 (109 CFU) (109 CFU) (109 CFU) 
65 
was achieved in the group receiving IpaB and IpaD+dmLT 
i.n. Animals vaccinated i.d. with the medium dose, exhibited 
Sera, tears (for measurement of secretory IgA) and fecal 
samples were collected prior to the first dose and 2 weeks 
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following each dose to examine immune responses to each 
antigen included. Four weeks after the last immunization the 
guinea pigs were challenged intraocularly with S. jlexneri 2a 
2457T (1-5x107CFU). 
34 
Summary of Guinea Pig Studies. The guinea pig serves as 
an alternative model for assessing the immunogenicity and 
protective capacity of Shigella vaccines. The most protec-
tive regimen in these studies was i.n. immunization with 
5 IpaB+IpaD+dmLT. The combined efficacy of this regimen 
from the 2 experiments was 46%. 
Challenge results are shown in Table 5. 100% of animals 
immunized with the positive control strain CVD 1208S were 
protected against challenge. There was 100% attack rate in 
the negative control Group C immunized with PBS. Intra-
dermal immunization with IpaB+IpaD+/-dmLT did not pro-
vide protection against challenge. Intranasal immunization 10 
with IpaB+IpaD+dmLT conferred 33% protection against 
challenge. However, the progression of disease in this group 
was slower than that in Groups A, B or C (FIG. 40). 
Example 9 
Immunogenicity of Shigella IpaB/IpaD with dmLT 
Administered Intradermally to Piglets 
TABLE 5 
Protection Against Challenge Following Intradermal Immunization. 
Due to the similarity of their immune response and skin 
thickness with humans, piglets were also chosen as an 
15 animal model. Piglets were immunized three times, two 
weeks apart either intradermally, sublingually or a combi-
nation of the two (Table 6). 
#animals reaching an 
eye score of "4" at any 
time point post 
challenge/total Attack PE against 
Vaccination Group #animals Rate PBS 
A(n- 10) 10/10 100% 0% 
IpaB + IpaD (i.d.) 
B (n - 10) 10/10 100% 0% 
IpaB + IpaD + dmLT 
(i.d.) 
C (n - 9) 9/9 100% 0% 
PBS (i.d.) 
D (n - 9) 6/9 67% 33% 
IpaB + IpaD + dmLT 
(i.n.) 
E (n - 5) 0/5 0% 100% 
CVD 1208S (i.n.) 
Immunology data was compiled to assess serum IgG and 
mucosa! (tears and fecal) IgAresponses to each antigen. All 
animals that were immunized with IpaB (Groups A, Band 
20 
25 
30 
35 
D) responded with strong serum IgG anti-IpaB responses 
following 2 doses (FIGS. 41A and B). Neither the route of 
immunization, i.d. or i.n. nor the presence of dmLT affected 40 
the magnitude of serum anti-IpaB responses. Mucosa! anti-
IpaB IgA antibodies in tears were very high following i.n. 
immunization and moderate following i.d. immunization, 
but only in the presence of dmLT (Group B). Animals in 
Group E, immunized with CVD 1208S responded with 45 
strong anti-IpaB IgG and IgA titers. Serum IgG responses to 
IpaD were elicited in Groups A, B, and D at approximately 
equivalent levels. Anti-IpaD titers were 5 to 10-fold lower 
than titers to IpaB (FIGS. 42A and B). 
Mucosa! anti-IpaD IgA was only measured in Group D, 50 
immunized by the i.n. route. Immunization with CVD 1208S 
did not elicit serum or mucosa! anti-IpaD responses. Serum 
anti-dmLT IgG responses were elicited in Groups B, and D 
(FIGS. 43A and B). Responses following i.n. immunization 
were significantly higher than those following i.d. immuni- 55 
zation. Mucosa! anti-dmLT IgA was only elicited in Group 
D following i.n. immunization. As expected serum and 
mucosa! responses to S.jlexneri 2a LPS were measured only 
in Group E, immunized with CVD 1208S (FIGS. 44A and 
B). Mucosa! responses to LPS following intranasal inocu- 60 
lation with live attenuated strains are consistently strong 
responses 
Conclusions from Intradermal Immunization. Intradermal 
immunization was able to elicit serum anti-IpaB and anti-
IpaD responses equivalent to those elicited by intranasal 65 
immunization. However, i.d. immunization did not stimulate 
mucosa! IgA responses to IpaB, IpaD or dmLT. 
TABLE 6 
Immunogenicity of Shigella IpaB/IpaD with dmLT 
administered intradermally to piglets. 
Group Pigs Description 
84-A-SL + ID 338 Sublingual, PBS; Intradermal, PBS 
84-B-ID 2 328, Intradermal, IpaB 250 ug + IpaD 
329 250 ug (High Dose) 
84-C-ID 2 330, Intradermal, IpaB 25 ug + IpaD 
331 25 ug + dmLT 10 ug (Low Dose) 
84-D-ID 2 332, Intradermal, IpaB 250 ug + IpaD 
333 250 ug + dmLT 10 ug (High Dose) 
84-E-SL 2 334, Sublingual, IpaB 2.5 mg + IpaD 
335 2.5 mg + dmLT 30 ug 
84-F-SL + ID 2 336, Sublingual, IpaB 2.5 mg + IpaD 
337 2.5 mg + dmLT 30 ug; Intradermal, 
IpaB 250 ug + IpaD 250 ug + dmLT 
30 
ug (High Dose) 
Total 11 
Immune responses were measured at the time of immu-
nization and two weeks after the last immunization. 
Although a serum IgG response was elicited by IpaB+IpaD 
alone, the highest response was seen after admixing dmLT 
(FIG. 45). Interestingly, the dose of IpaB did not impact 
serum IgG. In contrast, a 10-fold increase in IpaD lead to an 
increase is anti-IpaD IgG. Sublingual administration did not 
induce a serum IgG response against either IpaB or IpaD, 
but the response could be boosted to the sublingual level 
after sublingual immunization. IgA titers were assessed in 
serum, vaginal washes and saliva (FIG. 46). 
Example 10 
Protection Studies of the Fusion Protein in Mice 
The protective efficacy of the fusion protein was tested 
using DB fusion or DB fusion plus dmLT, in comparison to 
vehicle (PBS) and IPAB+IpaD+dmLT. The results are 
shown in FIG. 47. As can be seen, mice which received the 
DB fusion together with dmLT had a greater than 70% 
survival rate when challenged with S jlexneri and near 100% 
survival rate when challenged with S. sonnei. These results 
demonstrate cross-species protection against challenge by 
vaccination with the DB fusion protein. 
While the invention has been described in terms of its 
preferred embodiments, those skilled in the art will recog-
nize that the invention can be practiced with modification 
within the spirit and scope of the appended claims. Accord-
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ingly, the present invention should not be limited to the 
embodiments as described above, but should further include 
all modifications and equivalents thereof within the spirit 
and scope of the description provided herein. 
as well as those inherent therein. While presently preferred 
embodiments have been described for purposes of this 
disclosure, numerous changes and modifications will be 
apparent to those skilled in the art. Such changes and 
Thus, the present invention is well adapted to carry out the 
objects and attain the ends and advantages mentioned above 
5 modifications are encompassed within the spirit of this 
invention as defined by the appended claims. 
<160> NUMBER OF SEQ ID NOS, 4 
<210> SEQ ID NO 1 
<211> LENGTH, 580 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Shigella flexneri 
<400> SEQUENCE, 1 
Met His Asn Val Ser Thr Thr Thr Thr Gly Phe Pro Leu Ala Lys Ile 
1 5 10 15 
Leu Thr Ser Thr Glu Leu Gly Asp Asn Thr Ile Gln Ala Ala Asn Asp 
20 25 30 
Ala Ala Asn Lys Leu Phe Ser Leu Thr Ile Ala Asp Leu Thr Ala Asn 
35 40 45 
Gln Asn Ile Asn Thr Thr Asn Ala His Ser Thr Ser Asn Ile Leu Ile 
50 55 60 
Pro Glu Leu Lys Ala Pro Lys Ser Leu Asn Ala Ser Ser Gln Leu Thr 
65 70 75 80 
Leu Leu Ile Gly Asn Leu Ile Gln Ile Leu Gly Glu Lys Ser Leu Thr 
85 90 95 
Ala Leu Thr Asn Lys Ile Thr Ala Trp Lys Ser Gln Gln Gln Ala Arg 
100 105 110 
Gln Gln Lys Asn Leu Glu Phe Ser Asp Lys Ile Asn Thr Leu Leu Ser 
115 120 125 
Glu Thr Glu Gly Leu Thr Arg Asp Tyr Glu Lys Gln Ile Asn Lys Leu 
130 135 140 
Lys Asn Ala Asp Ser Lys Ile Lys Asp Leu Glu Asn Lys Ile Asn Gln 
145 150 155 160 
Ile Gln Thr Arg Leu Ser Asn Leu Asp Pro Glu Ser Pro Glu Lys Lys 
165 170 175 
Lys Leu Ser Arg Glu Glu Ile Gln Leu Thr Ile Lys Lys Asp Ala Ala 
180 185 190 
Val Lys Asp Arg Thr Leu Ile Glu Gln Lys Thr Leu Ser Ile His Ser 
195 200 205 
Lys Leu Thr Asp Lys Ser Met Gln Leu Glu Lys Glu Ile Asp Ser Phe 
210 215 220 
Ser Ala Phe Ser Asn Thr Ala Ser Ala Glu Gln Leu Ser Thr Gln Gln 
225 230 235 240 
Lys Ser Leu Thr Gly Leu Ala Ser Val Thr Gln Leu Met Ala Thr Phe 
245 250 255 
Ile Gln Leu Val Gly Lys Asn Asn Glu Glu Ser Leu Lys Asn Asp Leu 
260 265 270 
Ala Leu Phe Gln Ser Leu Gln Glu Ser Arg Lys Thr Glu Met Glu Arg 
275 280 285 
Lys Ser Asp Glu Tyr Ala Ala Glu Val Arg Lys Ala Glu Glu Leu Asn 
290 295 300 
Arg Val Met Gly Cys Val Gly Lys Ile Leu Gly Ala Leu Leu Thr Ile 
305 310 315 320 
Val Ser Val Val Ala Ala Ala Phe Ser Gly Gly Ala Ser Leu Ala Leu 
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-continued 
325 330 335 
Ala Ala Val Gly Leu Ala Leu Met Val Thr Asp Ala Ile Val Gln Ala 
340 345 350 
Ala Thr Gly Asn Ser Phe Met Glu Gln Ala Leu Asn Pro Ile Met Lys 
355 360 365 
Ala Val Ile Glu Pro Leu Ile Lys Leu Leu Ser Asp Ala Phe Thr Lys 
370 375 380 
Met Leu Glu Gly Leu Gly Val Asp Ser Lys Lys Ala Lys Met Ile Gly 
385 390 395 400 
Ser Ile Leu Gly Ala Ile Ala Gly Ala Leu Val Leu Val Ala Ala Val 
405 410 415 
Val Leu Val Ala Thr Val Gly Lys Gln Ala Ala Ala Lys Leu Ala Glu 
420 425 430 
Asn Ile Gly Lys Ile Ile Gly Lys Thr Leu Thr Asp Leu Ile Pro Lys 
435 440 445 
Phe Leu Lys Asn Phe Ser Ser Gln Leu Asp Asp Leu Ile Thr Asn Ala 
450 455 460 
Val Ala Arg Leu Asn Lys Phe Leu Gly Ala Ala Gly Asp Glu Val Ile 
465 470 475 480 
Ser Lys Gln Ile Ile Ser Thr His Leu Asn Gln Ala Val Leu Leu Gly 
485 490 495 
Glu Ser Val Asn Ser Ala Thr Gln Ala Gly Gly Ser Val Ala Ser Ala 
500 505 510 
Val Phe Gln Asn Ser Ala Ser Thr Asn Leu Ala Asp Leu Thr Leu Ser 
515 520 525 
Lys Tyr Gln Val Glu Gln Leu Ser Lys Tyr Ile Ser Glu Ala Ile Glu 
530 
Lys Phe Gly Gln Leu 
545 
Ser Asn Ser Gln 
Gln Thr Thr Ala 
580 
Ala 
565 
<210> SEQ ID NO 2 
<211> LENGTH, 332 
<212> TYPE, PRT 
535 
Gln Glu Val Ile Ala 
550 
Asn Arg Thr Asp Val 
570 
<213> ORGANISM, Shigella flexneri 
<400> SEQUENCE, 2 
540 
Asp Leu Leu Ala Ser Met 
555 560 
Ala Lys Ala Ile Leu Gln 
575 
Met Asn Ile Thr Thr Leu Thr Asn Ser Ile Ser Thr Ser Ser Phe Ser 
1 5 10 15 
Pro Asn Asn Thr Asn Gly Ser Ser Thr Glu Thr Val Asn Ser Asp Ile 
20 25 30 
Lys Thr Thr Thr Ser Ser His Pro Val Ser Ser Leu Thr Met Leu Asn 
35 40 45 
Asp Thr Leu His Asn Ile Arg Thr Thr Asn Gln Ala Leu Lys Lys Glu 
50 55 60 
Leu Ser Gln Lys Thr Leu Thr Lys Thr Ser Leu Glu Glu Ile Ala Leu 
65 70 75 80 
His Ser Ser Gln Ile Ser Met Asp Val Asn Lys Ser Ala Gln Leu Leu 
85 90 95 
Asp Ile Leu Ser Arg Asn Glu Tyr Pro Ile Asn Lys Asp Ala Arg Glu 
100 105 110 
38 
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-continued 
Leu Leu His Ser Ala Pro Lys Glu Ala Glu Leu Asp Gly Asp Gln Met 
115 120 125 
Ile Ser His Arg Glu Leu Trp Ala Lys Ile Ala Asn Ser Ile Asn Asp 
130 135 140 
Ile Asn Glu Gln Tyr Leu Lys Val Tyr Glu His Ala Val Ser Ser Tyr 
145 150 155 160 
Thr Gln Met Tyr Gln Asp Phe Ser Ala Val Leu Ser Ser Leu Ala Gly 
165 170 175 
Trp Ile Ser Pro Gly Gly Asn Asp Gly Asn Ser Val Lys Leu Gln Val 
180 185 190 
Asn Ser Leu Lys Lys Ala Leu Glu Glu Leu Lys Glu Lys Tyr Lys Asp 
195 200 205 
Lys Pro Leu Tyr Pro Ala Asn Asn Thr Val Ser Gln Glu Gln Ala Asn 
210 215 220 
Lys Trp Leu Thr Glu Leu Gly Gly Thr Ile Gly Lys Val Ser Gln Lys 
225 230 235 240 
Asn Gly Gly Tyr Val Val Ser Ile Asn Met Thr Pro Ile Asp Asn Met 
245 250 255 
Leu Lys Ser Leu Asp Asn Leu Gly Gly Asn Gly Glu Val Val Leu Asp 
260 265 270 
Asn Ala Lys Tyr Gln Ala Trp Asn Ala Gly Phe Ser Ala Glu Asp Glu 
275 280 285 
Thr Met Lys Asn Asn Leu Gln Thr Leu Val Gln Lys Tyr Ser Asn Ala 
290 295 300 
Asn Ser Ile Phe Asp Asn Leu Val Lys Val Leu Ser 
305 310 315 
Ser Cys Thr Asp Thr Asp Lys Leu Phe Leu His Phe 
325 330 
<210> SEQ ID NO 3 
<211> LENGTH, 155 
<212> TYPE, PRT 
<213> ORGANISM, Shigella flexneri 
<400> SEQUENCE, 3 
Ser Thr Ile Ser 
320 
Met Ser Leu Asn Ile Thr Glu Asn Glu Ser Ile Ser Thr Ala Val Ile 
1 5 10 15 
Asp Ala Ile Asn Ser Gly Ala Thr Leu Lys Asp Ile Asn Ala Ile Pro 
20 25 30 
Asp Asp Met Met Asp Asp Ile Tyr Ser Tyr Ala Tyr Asp Phe Tyr Asn 
35 40 45 
Lys Gly Arg Ile Glu Glu Ala Glu Val Phe Phe Arg Phe Leu Cys Ile 
50 55 60 
Tyr Asp Phe Tyr Asn Val Asp Tyr Ile Met Gly Leu Ala Ala Ile Tyr 
65 70 75 80 
Gln Ile Lys Glu Gln Phe Gln Gln Ala Ala Asp Leu Tyr Ala Val Ala 
85 90 95 
Phe Ala Leu Gly Lys Asn Asp Tyr Thr Pro Val Phe His Thr Gly Gln 
100 105 110 
Cys Gln Leu Arg Leu Lys Ala Pro Leu Lys Ala Lys Glu Cys Phe Glu 
115 120 125 
Leu Val Ile Gln His Ser Asn Asp Glu Lys Leu Lys Ile Lys Ala Gln 
130 135 140 
Ser Tyr Leu Asp Ala Ile Gln Asp Ile Lys Glu 
145 150 155 
40 
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<210> SEQ ID NO 4 
<211> LENGTH, 914 
<212> TYPE, PRT 
41 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
-continued 
<223> OTHER INFORMATION, Synthetic chimeric protein 
<400> SEQUENCE, 4 
Met Asn Ile Thr Thr Leu Thr Asn Ser Ile Ser Thr Ser Ser Phe Ser 
1 5 10 15 
Pro Asn Asn Thr Asn Gly Ser Ser Thr Glu Thr Val Asn Ser Asp Ile 
20 25 30 
Lys Thr Thr Thr Ser Ser His Pro Val Ser Ser Leu Thr Met Leu Asn 
35 40 45 
Asp Thr Leu His Asn Ile Arg Thr Thr Asn Gln Ala Leu Lys Lys Glu 
50 55 60 
Leu Ser Gln Lys Thr Leu Thr Lys Thr Ser Leu Glu Glu Ile Ala Leu 
65 70 75 80 
His Ser Ser Gln Ile Ser Met Asp Val Asn Lys Ser Ala Gln Leu Leu 
85 90 95 
Asp Ile Leu Ser Arg Asn Glu Tyr Pro Ile Asn Lys Asp Ala Arg Glu 
100 105 110 
Leu Leu His Ser Ala Pro Lys Glu Ala Glu Leu Asp Gly Asp Gln Met 
115 120 125 
Ile Ser His Arg Glu Leu Trp Ala Lys Ile Ala Asn Ser Ile Asn Asp 
130 135 140 
Ile Asn Glu Gln Tyr Leu Lys Val Tyr Glu His Ala Val Ser Ser Tyr 
145 150 155 160 
Thr Gln Met Tyr Gln Asp Phe Ser Ala Val Leu Ser Ser Leu Ala Gly 
165 170 175 
Trp Ile Ser Pro Gly Gly Asn Asp Gly Asn Ser Val Lys Leu Gln Val 
180 185 190 
Asn Ser Leu Lys Lys Ala Leu Glu Glu Leu Lys Glu Lys Tyr Lys Asp 
195 200 205 
Lys Pro Leu Tyr Pro Ala Asn Asn Thr Val Ser Gln Glu Gln Ala Asn 
210 215 220 
Lys Trp Leu Thr Glu Leu Gly Gly Thr Ile Gly Lys Val Ser Gln Lys 
225 230 235 240 
Asn Gly Gly Tyr Val Val Ser Ile Asn Met Thr Pro Ile Asp Asn Met 
245 250 255 
Leu Lys Ser Leu Asp Asn Leu Gly Gly Asn Gly Glu Val Val Leu Asp 
260 265 270 
Asn Ala Lys Tyr Gln Ala Trp Asn Ala Gly Phe Ser Ala Glu Asp Glu 
275 280 285 
Thr Met Lys Asn Asn Leu Gln Thr Leu Val Gln Lys Tyr Ser Asn Ala 
290 295 300 
Asn Ser Ile Phe Asp Asn Leu Val Lys Val Leu Ser Ser Thr Ile Ser 
305 310 315 320 
Ser Cys Thr Asp Thr Asp Lys Leu Phe Leu His Phe Leu Glu Met His 
325 330 335 
Asn Val Ser Thr Thr Thr Thr Gly Phe Pro Leu Ala Lys Ile Leu Thr 
340 345 350 
Ser Thr Glu Leu Gly Asp Asn Thr Ile Gln Ala Ala Asn Asp Ala Ala 
355 360 365 
42 
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43 
-continued 
Asn Lys Leu Phe Ser Leu Thr Ile Ala Asp Leu Thr Ala Asn Gln Asn 
370 375 380 
Ile Asn Thr Thr Asn Ala His Ser Thr Ser Asn Ile Leu Ile Pro Glu 
385 390 395 400 
Leu Lys Ala Pro Lys Ser Leu Asn Ala Ser Ser Gln Leu Thr Leu Leu 
405 410 415 
Ile Gly Asn Leu Ile Gln Ile Leu Gly Glu Lys Ser Leu Thr Ala Leu 
420 425 430 
Thr Asn Lys Ile Thr Ala Trp Lys Ser Gln Gln Gln Ala Arg Gln Gln 
435 440 445 
Lys Asn Leu Glu Phe Ser Asp Lys Ile Asn Thr Leu Leu Ser Glu Thr 
450 455 460 
Glu Gly Leu Thr Arg Asp Tyr Glu Lys Gln Ile Asn Lys Leu Lys Asn 
465 470 475 480 
Ala Asp Ser Lys Ile Lys Asp Leu Glu Asn Lys Ile Asn Gln Ile Gln 
485 490 495 
Thr Arg Leu Ser Asn Leu Asp Pro Glu Ser Pro Glu Lys Lys Lys Leu 
500 505 510 
Ser Arg Glu Glu Ile Gln Leu Thr Ile Lys Lys Asp Ala Ala Val Lys 
515 520 525 
Asp Arg Thr Leu Ile Glu Gln Lys Thr Leu Ser Ile His Ser Lys Leu 
530 535 540 
Thr Asp Lys Ser Met Gln Leu Glu Lys Glu Ile Asp Ser Phe Ser Ala 
545 550 555 560 
Phe Ser Asn Thr Ala Ser Ala Glu Gln Leu Ser Thr Gln Gln Lys Ser 
565 570 575 
Leu Thr Gly Leu Ala Ser Val Thr Gln Leu Met Ala Thr Phe Ile Gln 
580 585 590 
Leu Val Gly Lys Asn Asn Glu Glu Ser Leu Lys Asn Asp Leu Ala Leu 
595 600 605 
Phe Gln Ser Leu Gln Glu Ser Arg Lys Thr Glu Met Glu Arg Lys Ser 
610 615 620 
Asp Glu Tyr Ala Ala Glu Val Arg Lys Ala Glu Glu Leu Asn Arg Val 
625 630 635 640 
Met Gly Cys Val Gly Lys Ile Leu Gly Ala Leu Leu Thr Ile Val Ser 
645 650 655 
Val Val Ala Ala Ala Phe Ser Gly Gly Ala Ser Leu Ala Leu Ala Ala 
660 665 670 
Val Gly Leu Ala Leu Met Val Thr Asp Ala Ile Val Gln Ala Ala Thr 
675 680 685 
Gly Asn Ser Phe Met Glu Gln Ala Leu Asn Pro Ile Met Lys Ala Val 
690 695 700 
Ile Glu Pro Leu Ile Lys Leu Leu Ser Asp Ala Phe Thr Lys Met Leu 
705 710 715 720 
Glu Gly Leu Gly Val Asp Ser Lys Lys Ala Lys Met Ile Gly Ser Ile 
725 730 735 
Leu Gly Ala Ile Ala Gly Ala Leu Val Leu Val Ala Ala Val Val Leu 
740 745 750 
Val Ala Thr Val Gly Lys Gln Ala Ala Ala Lys Leu Ala Glu Asn Ile 
755 760 765 
Gly Lys Ile Ile Gly Lys Thr Leu Thr Asp Leu Ile Pro Lys Phe Leu 
770 775 780 
44 
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45 46 
-continued 
Lys Asn Phe Ser Ser Gln Leu Asp Asp Leu Ile Thr Asn Ala Val Ala 
785 790 795 800 
Arg Leu Asn Lys Phe Leu Gly Ala Ala Gly Asp Glu Val Ile Ser Lys 
805 810 815 
Gln Ile Ile Ser Thr His Leu Asn Gln Ala Val Leu Leu Gly Glu Ser 
820 825 830 
Val Asn Ser Ala Thr Gln Ala Gly Gly Ser Val Ala Ser Ala Val Phe 
835 840 845 
Gln Asn Ser Ala Ser Thr Asn Leu Ala Asp Leu Thr Leu Ser Lys Tyr 
850 855 860 
Gln Val Glu Gln Leu Ser Lys Tyr Ile Ser Glu Ala Ile Glu Lys Phe 
865 870 875 880 
Gly Gln Leu Gln Glu Val Ile Ala Asp Leu Leu Ala Ser Met Ser Asn 
885 890 
Ser Gln Ala Asn Arg Thr Asp Val Ala Lys Ala Ile Leu 
900 905 
Thr Ala 
What is claimed is: 
1. A cross-protective, O-serotype independent vaccine 
against Shigella in a form suitable for administration to an 
animal, comprising at least one fusion protein comprising 
IpaB and IpaD, 
wherein said vaccine is free of Shigella lipopolysaccha-
ride (LPS). 
2. The cross-protective, O-serotype independent vaccine 
of claim 1, wherein said vaccine comprises a complex of 
i) said fusion protein comprising IpaB and IpaD; and 
ii) IpgC. 
Gln 
910 
25 
895 
Gln Thr 
3. The vaccine of claim 1, wherein said fusion protein is 
or includes SEQ ID NO:4. 
4. A fusion protein that is or includes SEQ ID NO:4. 
5. A cross-protective, O-serotype independent vaccine 
against Shigella that is comprised of a fusion protein oflpaB 
30 
and IpaD, 
wherein said vaccine is free of Shigella lipopolysaccha-
ride (LPS). 
6. The vaccine of claim 5, wherein said fusion protein is 
or includes SEQ ID NO:4. 
* * * * * 
